Risk Factor Summary
The following summary highlights the material
risks that may affect our business, operating results, financial condition and prospects, as more fully described in the pages that follow
this summary.
|
·
|
If our competitors receive FDA approval for treatments or vaccines for COVID-19, our commercial opportunity may be reduced or eliminated,
if such treatments directly compete for the same segment of patients that lenzilumab targets or indirectly compete for the same patients
by preventing hospitalization.
|
|
·
|
The scientific rationale behind the hypothesis that GM-CSF is a cause, or the main cause, of the cytokine storm that leads to adverse
results in COVID-19 patients is still being tested and may not prove accurate.
|
|
·
|
We face risks related to the development, manufacturing and distribution of lenzilumab as a treatment for COVID-19, which has not
been granted an EUA or approved by FDA. We cannot provide any assurance that lenzilumab will receive an EUA or be approved by FDA.
|
|
·
|
Manufacturing problems at our third-party manufacturers or their requirements to displace our reserved manufacturing slots to comply
with government orders could cause inventory shortages and delay or impair our ability to obtain an EUA or BLA or other regulatory approval
or delay shipments of lenzilumab for commercial use, which may adversely affect our results of operations.
|
|
·
|
We may not be able to obtain materials or supplies necessary to conduct clinical trials or, following requisite regulatory authorizations
or approvals, to manufacture and sell our products, which could limit our ability to generate revenues.
|
|
·
|
If an EUA or other conditional marketing approval is granted for lenzilumab, we may be unable to accurately predict demand for lenzilumab
or to produce sufficient quantities on a timely basis to meet demand.
|
|
·
|
There can be no assurance that lenzilumab, even if approved, would ever become profitable, due to government or healthcare provider
or payer interest and public perception regarding vaccines and treatments for COVID-19 related complications. Competing products that
are subsequently developed also may diminish demand for lenzilumab or impair its profitability.
|
|
·
|
The regulatory pathway for lenzilumab is highly dynamic and continues to evolve and may result in unexpected or unforeseen challenges.
It may also be affected by the duration and the impact of the COVID-19 pandemic.
|
|
·
|
We currently have no internal sales and marketing capabilities and will rely on partners such as Eversana and other third parties
to market and sell lenzilumab if we attain an EUA or other regulatory approval for its commercialization, and any product candidates we
may successfully develop. We or they may not be able to effectively market and sell any such product candidates.
|
|
·
|
We may experience significant volatility in the market price of our common stock following announcements and releases regarding our
ongoing development of lenzilumab as a potential COVID-19 therapy.
|
|
·
|
We have a history of operating losses and we may never become profitable.
|
|
·
|
We will need to obtain additional financing to fund our operations and, if we are unable to obtain such financing, we may be unable
to complete the development and commercialization of our product candidates.
|
|
·
|
Our business depends on the success of our current product candidates. We cannot be certain that we will be able to obtain Emergency
Authorization, Conditional Marketing Authorization or regulatory approval for, or successfully commercialize, any of our product candidates.
|
|
·
|
The adoption of CAR-T therapies as the potential standard of care for treatment of certain cancers is uncertain and, and dependent
on the efforts of a limited number of market entrants, and if not adopted as anticipated, the market for lenzilumab or next-generation
gene-edited CAR-T therapies may be limited or not develop.
|
|
·
|
Our business could target benefits from various regulatory incentives, such as EUA, orphan drug exclusivity, breakthrough therapy
designation, fast track designation, and priority review, but we may not ultimately qualify for or benefit from these arrangements.
|
|
·
|
We may experience delays in commencing or conducting our clinical trials, in receiving data from third parties or in the continuation
or completion of clinical testing, which could result in increased costs to us, delay our ability to generate product candidate revenue
or, ultimately, render us unable to complete the development and commercialization of our product candidates.
|
|
·
|
We face risks associated with clinical operations abroad and we may not be able to receive conditional marketing approvals for lenzilumab
in COVID-19 patients in markets outside the U.S.
|
|
·
|
If our competitors develop similar or comparable treatments for the target indications of our product candidates that are approved
more quickly, marketed more successfully or are demonstrated to be safer or more effective than our product candidates, or if FDA approves
generic or biosimilar competitors to our products post-approval, our commercial opportunity will be reduced or eliminated.
|
|
·
|
We may encounter difficulties in managing our growth and expanding our operations successfully.
|
|
·
|
Even if we are able to obtain regulatory approval for our product candidates, we will continue to be subject to ongoing and extensive
regulatory requirements, and our failure to comply with these requirements could substantially harm our business.
|
|
·
|
Currently pending, threatened or future litigation or governmental proceedings or inquiries could result in material adverse consequences,
including judgments or settlements.
|
|
·
|
We may not be able to protect our intellectual property rights in the U.S. and throughout the world.
|
|
·
|
Our stock price is volatile and purchasers of our common stock could incur substantial losses.
|
|
·
|
Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured
liabilities.
|
In
addition to the other information set forth in this Quarterly Report on Form 10-Q and other filings we have made and will make in the
future with the SEC, you should carefully consider the following risk factors and uncertainties, which could materially affect our business,
financial condition or results of operations in future periods. Additional risks not currently known to us or that we currently deem to
be immaterial also may materially adversely affect our business, financial condition or results of operations in future periods.
Risks Related to Our Business and Industry
Risks Related to COVID-19 and Lenzilumab
The fluid and unpredictable nature of the COVID-19 pandemic,
which began in late 2019 and has spread worldwide, may affect our ability to conduct the clinical trial with NIH, the IMPACT Partnership
and SAHMRI and the University of Adelaide, delay the initiation of planned and future clinical trials, disrupt regulatory activities,
or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial volatility in the financial
markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business and operations.
In December 2019, an outbreak of the respiratory
illness COVID-19 caused by a strain of novel coronavirus, SARS-Cov-2, was first reported in China. The COVID-19 outbreak has spread worldwide,
causing many governments to implement measures to slow the spread of the outbreak through quarantines, strict travel restrictions, heightened
border scrutiny, and other measures. COVID-19 infections are widespread and as of April 30, 2021, in the U.S., there were over 32 million
cases, over 2.1 million hospitalizations and over 570 thousand deaths. Several vaccines have been developed which show efficacy in excess
of 90%, however the rollout of inoculations and the emergence of numerous COVID-19 variants lead us to believe the need for therapeutics
to treat COVID-19 currently exists and will continue to exist for the next several years. The outbreak and government measures taken in
response have had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply
chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical
services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the
outbreak and its effects on our business and operations are uncertain.
We and our third-party CRO clinical sites and
contract manufacturing organizations (“CMOs”) may experience disruptions in supply of product candidates and/or procuring
items that are essential for our research, development and manufacturing activities, including raw materials and components used
in the manufacturing of our product candidates, medical and laboratory supplies used in our clinical trials or preclinical studies, in
each case, for which there may be shortages because of ongoing efforts to address the outbreak. These delays have impacted our overall
manufacturing supply chain operations to date, and we continue to explore back up or alternative sources of supply, any future disruption
in the supply chain from the COVID-19 outbreak, or any continued outbreak could have a material adverse impact on our clinical trial
plans and business operations.
Additionally, we will seek to enroll patients
in several planned studies. Patients in our clinical trials are at sites located in many areas affected by COVID-19 and, as a result,
our trials may be impacted. In addition, even if sites are actively recruiting, we may face difficulties recruiting or retaining patients
in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of visiting or traveling to our clinical
trial sites because of the outbreak. Prolonged delays or closure to enrollment in our trials or patient discontinuations could have a
material adverse impact on our clinical trial plans and timelines.
In addition, our ability to collect all data requested
of patients enrolled in our clinical trials during this pandemic is being impacted to varying degrees by COVID-19. Clinical trial data
collection generally continues for each of our clinical trials, but at a slower pace, and in some instances, we encounter disruption of
collection of complete study data. This could have a material adverse impact on our data analysis.
The response to the COVID-19 pandemic may redirect
resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory
approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures
intended to limit in-person interactions.
Any negative impact that the COVID-19 pandemic
has on the ability of our suppliers to provide materials for our product candidates or on recruiting or retaining patients in our clinical
trials or our ability to collect patient data could cause delays to clinical trial activities including collection of the final results
from LIVE-AIR study, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates,
increase our operating expenses, and have a material adverse effect on our financial results. Furthermore, any negative impact that the
outbreak has on the ability of our CROs to deliver data sets and execute on experimentation has caused and could cause substantial delays
for our discovery activities and materially impact our ability to fuel our pipeline with new product candidates.
Any negative impact that the COVID-19 pandemic
has on recruiting or retaining patients in our clinical trials, obtaining complete clinical trial data or on the ability of our suppliers
to provide materials for our product candidates could cause additional delays to clinical trial and developmental activities, which could
materially and adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our
operating expenses, affect our ability to raise additional capital, and have a material adverse effect on our financial results.
The COVID-19 pandemic has caused significant volatility
in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds through
public offerings and may also impact the volatility of our stock price and trading in our stock. Moreover, the pandemic has significantly
impacted economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall
impact of the COVID-19 pandemic will be on our business. It has the potential to adversely affect our business, financial condition, results
of operations, and prospects.
If our competitors develop and receive FDA approval for treatments
or vaccines for COVID-19, our commercial opportunity may be reduced or eliminated, if such treatments directly compete for the same segment
of patients that lenzilumab targets or indirectly compete for the same patients by preventing hospitalization.
On October 22, 2020, FDA approved remdesivir for
use in adult and certain pediatric patients for the treatment of COVID-19 requiring hospitalization. Baricitinib has also been approved
for use with remdesivir for the treatment of COVID-19. Baricitinib may not be used with corticosteroids. Several neutralizing antibodies
have been approved to prevent progression in the early stages of infection. Three vaccines have been authorized by the FDA with efficacy
rates ranging from less than 50% in certain populations in excess of 90%. There are numerous other companies working on therapies to treat
COVID-19 and/or vaccines to prevent or treat COVID-19, including oral antiviral compounds. If additional competing therapies are approved,
such approval could have a material adverse impact on our ability to commercialize lenzilumab as a therapy for COVID-19. The speed at
which all parties are acting to create and test many treatments and vaccines for COVID-19 is unusual and evolving or changing plans or
priorities within the FDA and other branches of the U.S. government involved in the fight against the pandemic, including changes based
on new knowledge of COVID-19 and new COVID-19 variants This can all impact how the disease affects the human body and may significantly
affect the regulatory timeline for lenzilumab. In addition, there are numerous clinical trial programs in progress for COVID-19 therapies
which are all competing for largely the same patient population for enrollment. This problem is exacerbated by changing rates of infection
and spread, which make it challenging to ensure there are sufficient centers and patients to be enrolled in additional studies. Results
from clinical testing may raise new questions and require us to redesign proposed clinical trials. Many of our competitors and potential
competitors have substantially greater scientific, research, and product development capabilities, as well as greater financial, marketing,
sales and human resources capabilities than we do. In addition, many specialized biotechnology firms have formed collaborations with large,
established companies to support the research, development and commercialization of products that may be competitive with ours.
The scientific rationale behind the hypothesis
that GM-CSF is a cause, or the main cause, of the cytokine storm that leads to adverse results in COVID-19 patients is still being tested
and may not prove accurate.
The hypothesis that elevated
GM-CSF levels may contribute to cytokine storm-induced immune mechanisms that places patients at greater risk of ICU admission and mortality
with the current pandemic strain of coronavirus is unproven. However, a paper in Science Immunology attributed GM-CSF to be a key factor
in COVID-19. The data for this paper were drawn from the largest study conducted to date and the study was supported financially by the
UK government. While supportive of our hypothesis, additional clinical data will be needed to confirm the role of GM-CSF in patients with
COVID-19. Certain additional data on the role of GM-CSF are also the subject of publications as well as pre-publication papers that have
not been peer-reviewed and may not be substantiated. If this hypothesis is not ultimately proven through clinical trials which are underway,
the potential for lenzilumab to play a meaningful role in a COVID-19 therapy likely would decrease or be eliminated. We cannot assure
you that our exploratory efforts in this respect will be fruitful.
We face risks related to the development, manufacturing and distribution
of lenzilumab as a treatment for COVID-19, which has not been granted an EUA or approved by FDA. We cannot provide any assurance that
lenzilumab will receive an EUA or be approved by FDA.
While we achieved favorable results in our Phase
3 multi-center, randomized, placebo-controlled, double-blinded, clinical trial of lenzilumab as a potential treatment for COVID-19 , there
is no assurance of favorable results from future clinical trials, including the NIH sponsored ACTIV-5/BET-B or any other studies we may
initiate.
Based on a meeting, the FDA has requested that
the EUA application for lenzilumab include secondary endpoints and supplemental data analysis from the first arm of the Phase 3 study
(also known as LIVE-AIR), including those referenced in the MedRxiv publication, as well as additional stability and compatibility information
required for the CMC section of the EUA application. There can be no assurance that the data published on MedRxiv will be sufficient for
an EUA or that the FDA will not require additional information in order to grant an EUA. It is also possible that FDA and other regulatory
authorities may not grant an EUA or subsequently approve lenzilumab for the treatment of COVID-19, or that any such EUA or approval, if
granted, may have significant limitations on its use. Widespread uptake of a safe, effective, scalable and affordable vaccine may have
a negative impact on the demand for lenzilumab over the long term, even if an EUA or approval were issued, although substantial numbers
of patients may continue to be hospitalized until there is widespread vaccination/herd immunity, notwithstanding the impact of current
and future variants. As a result, we may never successfully commercialize lenzilumab in COVID-19 or realize a return on our significant
investment in the development, supply, and commercialization of lenzilumab for this purpose.
Furthermore, even if an EUA were granted to permit
lenzilumab to be commercialized for use in the treatment of COVID-19, the authorization is only in effect while it is determined that
a “Public Health Emergency” is still underway and might be expressly conditioned or limited by FDA. An EUA does not take the
place of the formal BLA submission, review and approval process. We intend to submit
a BLA to FDA in 2022, for the use of lenzilumab in hospitalized, hypoxic COVID-19 patients. Since BLAs typically require more than one
study, we are currently evaluating the extent to which ACTIV-5/BET-B may serve as a basis for a BLA-confirmatory study for lenzilumab.
There can be no assurance that the ACTIV-5/BET-B will be sufficient for a BLA or that the FDA will not require additional information
in order to grant a BLA. Furthermore, there is no assurance of favorable results from the ongoing ACTIV-5/BET-B clinical trial,
or that this trial will be completed in anticipated timelines or at all. It is also possible that FDA and other regulatory authorities
may not approve lenzilumab for the treatment of COVID-19, or that any marketing approvals, if granted, may have significant limitations
on its use. Further, we may make a strategic decision to discontinue development of lenzilumab in this indication if other parties are
successful in developing a more effective treatment for COVID-19. As a result, we may never successfully commercialize lenzilumab for
use in COVID-19 patients.
Manufacturing problems at our third-party manufacturers or their
requirements to displace our reserved manufacturing slots to comply with government orders could cause inventory shortages and delay or
impair our ability to obtain an EUA or BLA or other regulatory approval or delay shipments of lenzilumab for commercial use, which may
adversely affect our results of operations.
We believe that our ability to obtain an EUA and,
ultimately, a BLA to permit lenzilumab to be used commercially for patients with COVID-19 depends at least in part on our ability to demonstrate
to FDA that we will be able to scale the manufacturing to produce a sufficient quantity of dosages to address the potential demand for
the product. We have contracted and expect to continue to contract with third-party manufacturers to produce lenzilumab. We depend on
these third parties to perform the manufacturing of lenzilumab effectively, timely, and in compliance with Good Manufacturing Practices
(“GMP”), which are extensive regulations governing manufacturing processes, stability testing, record-keeping and quality
standards as defined by FDA. Similar regulations are in effect in other jurisdictions.
Our complete reliance on third-party manufacturers
to produce lenzilumab subjects us to additional risks, including the possible breach of the manufacturing agreement by the third party,
the possible cancellation, delay or modification of contracted manufacturing slots by the third party, or the termination or nonrenewal
of the agreement by the third party at a time that is costly or inconvenient for us. In addition, in an effort to increase the availability
of needed medical products, vaccinations or related therapies in response to the COVID-19 pandemic, governments have required and may
continue require our third-party manufacturers or our suppliers to allocate manufacturing capacity (for example pursuant to the U.S Defense
Production Act, “DPA”) in a way that adversely affects our ability to obtain regulatory approval for and to commercialize
lenzilumab . During the latter half of 2020, and continuing into 2021, it has become more challenging and expensive to obtain these slots
due to increased demand for production at our CMOs, many of which also manufacture vaccines and other therapeutics. Even after being reserved
and paid for, the manufacturing slots for which we contract are subject to risk of displacement as mandated from Rated Orders issued under
the DPA. This displacement risk has caused us to expend significant efforts to manage our supply chain and add additional CMOs. Despite
those efforts, we have experienced and expect to continue to experience shortages of raw materials and critical components we necessary
for our manufacturing processes. Accordingly, the inability to manage our manufacturing capacity could delay our ability to gain approval
and ultimately generate revenues from sales of lenzilumab.
Our third-party manufacturers are independent
entities subject to their own unique operational and financial risks that are out of our control. If we or any of these third-party manufacturers
fail to perform as required, this could cause delays in our clinical trials and applications for regulatory approval. Further, we may
have to pay the costs of manufacturing any batch that fails to pass quality inspection or meet regulatory approval. In addition, we, our
third-party manufacturers may only be able to produce some of our products at one or a limited number of facilities and, therefore, we
have limited manufacturing capacity for certain products, and we may not be able to locate additional or replacement facilities on a reasonable
basis or at all. Our sales of such products could also be adversely impacted by our reliance on such limited number of facilities. To
the extent these risks materialize and affect their performance obligations to us, our financial results may be adversely affected.
In addition, the process of manufacturing biologics
is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or
vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product
defects and other supply disruptions. If microbial, viral, foreign substances or other contaminations are discovered in our products or
in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period
of time to investigate and remedy the contamination. Lenzilumab produced in these facilities may be quarantined or recalled and not available
for clinical or commercial use. We have encountered and may continue to encounter these difficulties, our ability to manufacture and sell
any products that may be authorized or approved for commercial use could be impaired, which could have an adverse effect on our business.
We may not be able to obtain materials or supplies necessary
to conduct clinical trials or, following requisite regulatory authorizations or approvals, to manufacture and sell our products, which
could limit our ability to generate revenues.
We need access to certain supplies and products
to conduct our clinical trials and, if an EUA or BLA or other approval were to be received, to manufacture and sell our products. If we
are unable to purchase sufficient quantities of these materials or find suitable alternative materials in a timely manner, our development
efforts for our product candidates may be delayed or our ability to manufacture our products could be limited, which could limit our ability
to generate revenues.
Suppliers of key components and materials must
be named in the EUA, BLA or other marketing authorization application filed with the regulatory authority for any product candidate for
which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after
a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of
production and quality control to ensure full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory
authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities,
laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend
the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be
unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand, which could in turn decrease
our revenues and harm our business. In addition, if deliveries of materials from our suppliers were interrupted for any reason, we may
be unable to supply our product candidates in development for clinical trials or ship them to customers, if authorized or approved for
commercial use. In addition, some of our products and the materials that we utilize in our operations are manufactured at only one facility
or from a single vendor, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems
with any of the single suppliers we depend on, including in the event of a natural disaster, power or equipment failure or other difficulty,
may negatively impact our development and commercialization efforts.
A significant portion of the raw materials and
intermediates used to manufacture our product candidates are supplied by third-party manufacturers and corporate partners outside of the
U.S. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade
regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the U.S. from supplying
these materials could adversely affect our ability conduct our pending or contemplated clinical trials.
If we were to encounter any of these difficulties,
our ability to conduct clinical trials on product candidates and to manufacture and sell any products that may be authorized or approved
for commercial use could be impaired, which could have an adverse effect on our business.
Interim, topline or preliminary data from our clinical trials
that we announce or publish from time-to-time may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data.
From time-to-time, we may publicly disclose preliminary,
“topline” or other data from our clinical trials, which is based on a preliminary analysis of then-available data, and the
results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial.
We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had
the opportunity to fully and carefully evaluate all data. As a result, such results that we report may differ from future results of the
same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated.
Such data also remain subject to audit and verification procedures that may result in the final data being materially different from the
preliminary data we previously published. As a result, interim, topline, or preliminary data should be viewed with caution until the final
data are available and such data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes
may materially change as patient enrollment continues and more patient data become available. Adverse differences between such data and
final data could significantly harm our business prospects. Further, disclosure of interim, topline or preliminary data by us or by our
competitors could result in volatility in the price of shares of our common stock.
Further, others, including regulatory agencies,
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance
of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular
product candidate or product and our business in general. In addition, the information we choose to publicly disclose or to publish via
a preprint publication regarding a particular study or clinical trial is based on what is typically extensive information, and you or
others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any
information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities
or otherwise regarding a particular drug, product candidate or our business. If the top-line data that we report differ from actual results,
or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize
in our current or any our future product candidate, our business, operating results, prospects or financial condition may be harmed.
If an EUA or other conditional marketing approval is granted
for lenzilumab, we may be unable to accurately predict demand for lenzilumab or to produce sufficient quantities on a timely basis to
meet demand.
We may be unable to accurately predict demand
for lenzilumab, or other approved or unapproved products for COVID-19, as demand depends on a number of factors, including rollout and
effectiveness of approved vaccines, competing drug products and other treatments that may be developed for COVID-19 and other illnesses
and conditions and federal and state social measures design to slow the spread of COVID-19. If lenzilumab is commercialized, we may be
unsuccessful in estimating user demand and may not be effective in matching inventory levels and locations to actual end user demand,
in particular if the COVID-19 pandemic, including emerging variants, is effectively contained or the risk of patients being hospitalized
as a result of coronavirus infection is significantly diminished. In addition, adverse changes in economic conditions, increased competition,
including through approved vaccines or other therapeutic, or other factors may cause hospitals or other users or distributors of lenzilumab
to reduce inventories of our products, which would reduce their orders for lenzilumab, even if end user demand has not changed. As a result,
even if lenzilumab receives an EUA or BLA approval for use in COVID-19 patients, our revenues may be difficult to predict and vulnerable
to extreme fluctuations.
There can be no assurance that lenzilumab,
even if approved, would ever become profitable, due to government or healthcare provider or payer interest and public perception regarding
vaccines and treatments for COVID-19 related complications.
As a result of the emergency
situations in many countries, there is a heightened risk that a COVID-19 therapy or other treatments for COVID-19 pneumonia
and symptoms may be subject to adverse governmental actions in certain countries, including intellectual property expropriation, compulsory
licenses, strict price controls or other actions. Additionally, we may need to, or we may be required by governmental or non-governmental authorities
to, set aside specific quantities of doses of lenzilumab for designated purposes or geographic areas. We may face challenges related to
the allocation of supply of lenzilumab, particularly with respect to geographic distribution. Thus, even if lenzilumab is approved, such
governmental actions may limit our ability to recoup our current and future expenses incurred to develop and commercialize lenzilumab.
Furthermore, public sentiment
regarding commercialization of a COVID-19 therapy or other treatment may limit or negate our ability to generate revenues from sales of
lenzilumab. Given that COVID-19 has been designated as a National Emergency and represents an urgent public health crisis, we
are likely to face significant public attention and scrutiny over any future business models and pricing decisions with respect to lenzilumab.
If we are unable to successfully manage these risks, we could face significant reputational harm, which could negatively affect the price
of our common stock.
The regulatory pathway for lenzilumab
is highly dynamic and continues to evolve and may result in unexpected or unforeseen challenges. It may also be affected by the duration
and the impact of the COVID-19 pandemic.
To date, lenzilumab has
moved rapidly through the regulatory review process of FDA. The speed at which all parties are acting to create and test many therapeutics
and vaccines for COVID-19 is unusual and evolving or changing plans or priorities within FDA and foreign regulatory authorities,
including changes based on new knowledge of COVID-19 and how the disease affects the human body, may significantly affect the
regulatory timeline for lenzilumab. Results from clinical testing may raise new questions and require us to redesign proposed clinical
trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects.
Although we intend to
design any future clinical trials for lenzilumab in accordance with FDA and other applicable regulatory guidance, we cannot be certain
that, as the regulatory pathway continues to evolve, we will be able to complete a clinical trial in accordance with FDA’s guidance
and regulations then in effect. A failure to complete a clinical trial in accordance with guidance and regulations then in effect could
impair our ability to obtain approval for lenzilumab, which may adversely affect our operating results, reputation and ability to raise
capital and enter into or maintain collaborations to advance lenzilumab.
Additionally, FDA has
the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or
life-threatening diseases or conditions when there are no adequate, approved, and available alternatives. If we are granted an EUA for
lenzilumab, we would be able to commercialize lenzilumab prior to FDA approval. However, because EUA authorization is only in effect while
it is determined that a Public Health Emergency is underway, FDA may revoke an EUA where it is determined that the underlying Public Health
Emergency no longer exists or warrants such authorization. Widespread vaccination programs and potential “herd immunity” may
result in the public perception that the medical emergency posed by COVID-19 has diminished to the point of no longer necessitating EUA
for therapies for COVID-19. Accordingly, even if granted, we cannot predict how long, if ever, an EUA would remain in place. Such revocation
could adversely impact our business in a variety of ways, including if lenzilumab is not yet approved by FDA and if we and our manufacturing
partners have invested in the supply chain to provide lenzilumab under an EUA.
Even if EUA or regulatory approval is
received for lenzilumab, the later discovery of previously unknown problems associated with the use of lenzilumab may result in restrictions,
including withdrawal of the product from the market, and lead to significant liabilities and reputational damage.
Because the path to marketing
approval of any vaccine for COVID-19, or drug used to treat COVID-19 pneumonia or other symptoms is unclear, lenzilumab may be widely
used and in circulation in the U.S. or another country prior to our receipt of marketing approval. Unexpected safety issues, including
any that we have not yet observed in our Phase 3 clinical trial for lenzilumab, could lead to patient harm and significant reputational
damage to us and our platforms going forward and other issues, including delays in our other programs, the need for re-design of
our clinical trial and the need for significant additional financial resources.
We also may be restricted
or prohibited from marketing or manufacturing lenzilumab, even after obtaining product approval, if previously unknown problems with lenzilumab
or its manufacture are subsequently discovered. We cannot provide assurance that newly discovered or developed safety issues will not
arise following regulatory approval. With the use of any drug product or treatment by a wide patient population, serious adverse events
may occur from time-to-time that did not arise in the clinical trials of the product or that initially appeared to be unrelated to the
vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Any such safety
issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely
affect our ability to generate revenue and our financial condition.
We currently have no internal sales and
marketing capabilities and will rely on partners such as Eversana and other third parties to market and sell lenzilumab if we attain an
EUA or other regulatory approval for its commercialization, and any product candidates we may successfully develop. We or they may not
be able to effectively market and sell any such product candidates.
While we have entered into several agreements
with commercial partners who will provide sales and marketing support as well as logistic and distribution services, we currently do not
have the internal sales and marketing infrastructure in place that would be necessary to sell and market products. As is the case with
many, if not most, small companies seeking to commercialize their products and who have not yet partnered with a larger biotech or pharmaceutical
company, we have engaged a contract commercial organization, Eversana, to serve as our end-to-end commercial partner in marketing and
selling lenzilumab, if authorized and/or approved, and have entered into other arrangements with distribution partners as described in
our 2020 Annual Report on Form 10-K under “Item 1. Business—Sales and Marketing.” There can be no assurance that our
partners will be effective in marketing and selling lenzilumab.
If we or Eversana fail to hire, train, retain
and manage qualified sales personnel, market our product successfully or on a cost-effective basis or otherwise terminate our agreement,
our ability to generate revenue will be limited and we will need to identify and retain an alternative third-party, or develop our own
sales and marketing capability. The establishment of an in-house sales and marketing operation can be expensive and time consuming and
could delay any product candidate launch.
We may experience significant volatility
in the market price of our common stock following announcements and releases regarding our ongoing development of lenzilumab as a
potential COVID-19 therapy.
Biopharmaceutical companies
that are developing potential therapeutics and vaccines to combat COVID-19, including our company, have experienced significant
volatility in the price of their securities upon publication of preclinical and clinical data as well as news about their development
programs. Since our initial announcement of our plans to develop lenzilumab as a therapy for COVID-19 patients, our common stock has experienced
wide variations in daily trading volume and price movements. The volatility in the price per share is further exacerbated by the large
percentage of retail shareholders. We expect that over the coming months we may make public several additional data, and clinical
and regulatory updates with respect to lenzilumab and our commercialization efforts for lenzilumab. We cannot predict public reaction
or the impact on the market price of our common stock once further announcements regarding lenzilumab or developments from our on-going
clinical trial are announced. Given the attention being paid to the COVID-19 pandemic and the public scrutiny of COVID-19 development
announcements and data releases to date, we expect that any public announcements we make in the coming months regarding the ongoing development
and commercialization of lenzilumab will attract significant attention and scrutiny and that, as a result, the price of our common
stock may be particularly volatile during this time.
Other Risks Related
to Our Business and Industry
We have a history of operating losses, we
expect to continue to incur losses, and we may never become profitable.
We have incurred net losses in nearly every year
since our inception. For the three months ended March 31, 2021, we incurred a net loss of $65.6 million, and we have an accumulated deficit
of $440.0 million as of March 31, 2021. Since inception, we have recognized a nominal amount of revenue from payments for license or collaboration
fees, $0.5 million of which was recognized in the first quarter of 2021. We expect to make substantial expenditures and incur additional
operating losses in the future to further develop and commercialize our product candidates. Our accumulated deficit is expected to increase
significantly as we continue our development and clinical trial efforts. Our ability to achieve and sustain profitability depends on obtaining
regulatory approvals for and successfully commercializing our product candidates, either alone or with third parties. We do not currently
have the required approvals to market any of our product candidates and we may never receive them. We may not be profitable even if we
or any future development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties
associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when
we will become profitable, if at all.
Our ability to execute on all of the initiatives in our development
pipeline is substantially dependent on third parties to plan and conduct the referenced studies and clinical trials.
Our success depends on our ability to negotiate
agreements with third parties with resources to plan and conduct the initiatives, studies and clinical trials we are pursuing. If we are
not able to reach agreements with current or future partners for it, we will not be able to execute on each of these particular initiatives,
studies and trials. Our inability to identify and complete negotiations with any such third party therefore could have a material and
adverse impact on our ability to pursue our business plan in respect of the applicable element of our pipeline, which in turn could have
a material adverse effect on our business.
We will need to obtain additional financing to fund our operations
and, if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our product candidates.
We believe that our cash
and cash equivalents will be sufficient to fund our planned operations and capital expenditure requirements for at least the next 12 months.
This evaluation is based on relevant conditions and events that are currently known or reasonably knowable. As a result, we could deplete
our available capital resources sooner than we currently expect, and a delay in obtaining or failure to obtain an EUA could further constrain
our cash resources. We have based these estimates on assumptions that may prove to be wrong, and our operating projections, including
our projected net revenue following the potential receipt of an EUA for lenzilumab in COVID-19 patients, may change as a result of many
factors currently unknown to us.
We may need to obtain additional financing to
fund our future operations, including for clinical development, manufacturing, distribution and commercialization of lenzilumab for patients
with COVID-19 and other indications including CAR-T, GvHD and CMML and our other product candidates. We may need to obtain additional
financing to conduct additional trials for the approval of our product candidates if requested by regulatory authorities in the U.S. and
other countries, and to complete the development of any additional product candidates we own or might acquire. Moreover, our fixed expenses
such as salaries, committed payments to our contract manufacturers, and other contractual commitments, are substantial and are expected
to increase in the future. Our need to raise funds will depend on a number of factors, including our ability to establish additional relationships
for the manufacture of lenzilumab and our ability to commence commercialization and begin generating revenues from product sales if lenzilumab
were to be issued an EUA and eventually approved under a BLA.
Until we can generate a sufficient amount of revenue,
we may finance future cash needs through public or private equity offerings, license agreements, grant financing and support from governmental
agencies, convertible debt, other debt financings including the Term Loan from Hercules, collaborations, strategic alliances and marketing,
supply, distribution or licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to
us, or at all. If adequate funds are not available, we may be required to delay or reduce the scope of or eliminate one or more of our
research or development programs, our commercialization efforts or our manufacturing commitments and capacity. We may seek to access the
public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at
that time. In addition, if we raise additional funds through collaborations, strategic alliances or marketing, supply, distribution, or
licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product
candidates or to grant licenses on terms that may not be favorable to us.
Our business depends on the success of our current product candidates.
We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our product candidates.
We have a limited pipeline
of product candidates and we do not plan to conduct active research at this time for discovery of new molecules or antibodies. We depend
on the successful continued development and regulatory approval of our current product candidates for our future business success. Since
the fall of 2017, our primary focus has been the clinical development of lenzilumab. We are also working to create next-generation gene-edited
CAR-T therapies using GM-CSF gene knockout technologies, as well as working to develop ifabotuzumab and related products. We will need
to successfully enroll and complete clinical trials of lenzilumab and ifabotuzumab, and potentially obtain regulatory approval to market
these products. The future clinical, regulatory and commercial success of our product candidates is subject to a number of risks, including
the following:
|
·
|
we may not be able to enroll adequate numbers of eligible patients in the clinical trials we propose to
conduct, whether alone or through collaborations, including the collaboration with NIH, the IMPACT Partnership, SAHMRI and the University
of Adelaide and other partnerships;
|
|
·
|
we may not have sufficient financial and other resources to fund our clinical trials or collaborations;
|
|
·
|
we may not be able to provide acceptable evidence of safety and efficacy for our product candidates;
|
|
·
|
the results of our clinical trials or collaborations may not meet the level of statistical or clinical
significance, or product safety, required to move to the next stage of development or, ultimately, obtain marketing approval from the
FDA;
|
|
·
|
we may not be able to obtain, maintain and enforce our patents and other intellectual property rights;
and
|
|
·
|
we may not be able to obtain and maintain commercial manufacturing arrangements with third-party manufacturers
or establish commercial-scale manufacturing capabilities.
|
Furthermore, even if we do
receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated
uses for which we may market the product. If any of our product candidates are unsuccessful, that could have a substantial negative impact
on our business.
Accordingly, we cannot assure
you that our product candidates will be successfully developed or commercialized. If we or any future development partners are unable
to develop, or obtain regulatory approval for or, if approved, successfully commercialize, one or more of our product candidates, we may
not be able to generate sufficient revenue to continue our business.
Our product candidates are at an early stage of development and
may not be successfully developed or commercialized.
Our product candidates are in the early stages
of development and will require substantial clinical development, testing, and regulatory approval prior to commercialization. Of the
large number of drugs in development, only a small percentage successfully completes the FDA regulatory approval process and are commercialized.
Accordingly, we cannot assure you that our product candidates will be successfully developed or commercialized. If we or any future development
partners are unable to develop, or obtain regulatory approval for or, if approved, successfully commercialize, one or more of our product
candidates, we may not be able to generate sufficient revenue to continue our business.
The adoption of CAR-T therapies as the potential standard of
care for treatment of certain cancers is uncertain, and dependent on the efforts of a limited number of market entrants, and if not adopted
as anticipated, the market for lenzilumab or next-generation gene-edited CAR-T therapies may be limited or not develop.
We are seeking to advance the development of lenzilumab
to address, among other things, the serious and potentially fatal side effects associated with CAR-T therapies and to improve the efficacy
of these treatments. We are also working to create next-generation gene-edited CAR-T therapies using GM-CSF gene knockout technologies.
Although five CAR-T therapies have been approved by FDA to date, the use of engineered T cells as a potential cancer treatment is a recent
development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical
community. The degree of market acceptance of any approved product candidates will depend on a number of factors, including:
|
·
|
the efficacy and safety as demonstrated in clinical trials;
|
|
·
|
the clinical indications for which the product candidate is approved;
|
|
·
|
acceptance by physicians, major operators of hospitals and clinics, and patients of the product candidate as a safe and effective
treatment;
|
|
·
|
the potential and perceived advantages of product candidates over alternative treatments;
|
|
·
|
the safety of product candidates seen in a broader patient group, including its use outside the approved indications;
|
|
·
|
competitive approaches to tackle similar issues;
|
|
·
|
the cost of treatment in relation to alternative treatments;
|
|
·
|
the availability of adequate reimbursement and pricing by payers;
|
|
·
|
relative convenience and ease of administration;
|
|
·
|
the prevalence and severity of adverse events;
|
|
·
|
the effectiveness of sales and marketing efforts; and
|
|
·
|
the ability to manage any unfavorable publicity relating to the product candidate.
|
If the medical and payer community is not sufficiently
persuaded of the safety, efficacy and cost-effectiveness of CAR-T therapy and the potential advantages of using lenzilumab compared to
existing and future therapeutics, and there is not significant market acceptance of CAR-T therapy as the standard of care for treatment
of certain cancers, the market for lenzilumab or next-generation gene-edited CAR-T therapies may be limited or not develop, and our stock
price could be adversely affected.
CAR-T therapies currently in early development purport to incorporate
technology that may minimize or eliminate the adverse side-effects and improve on efficacy, that we believe have impaired the uptake of
the approved CAR-T therapies. If these developing therapies are proven safer and equally or more efficacious in their proposed indications
and approved for use by FDA and other regulatory agencies, the market growth for the currently approved CAR-T therapies may be limited,
impairing demand for lenzilumab.
In recent years, several biotechnology companies
describing business plans focusing on development of CAR-T therapies have completed or announced they are pursuing initial public offerings
(“IPOs”). Several of these companies have described their belief that their therapies will not result in the same level of
CRS or NT as has been experienced in use of previously FDA-approved CAR-T therapies. While these products are in early-stage development,
the data is limited and these products have not yet been approved for use by FDA, if any such product were also proven equally efficacious
and subsequently approved, the market for lenzilumab may not develop or grow as anticipated. Recently the FDA approved Breyanzi™,
(liso-cel), a new CAR-T cell therapy for adults with relapsed or refractory Large B-cell Lymphoma. Grade ≥3 cytokine release syndrome
and Grade ≥3 neurologic toxicities following Breyanzi treatment occurred in 4% and 12% of patients, respectively. If new
CAR-T therapies with lower occurrences of CRS and NT are approved, the market for lenzilumab in conjunction with CAR-T therapy may be
diminished. Any such failure of a market for lenzilumab to develop could adversely affect our stock price. In addition, if new CAR-T therapies
that offer improved efficacy, either with or without improved safety, the market for lenzilumab in conjunction with CAR-T therapy may
be diminished.
Our business could target benefits from various regulatory incentives,
such as EUA, orphan drug exclusivity, breakthrough therapy designation, fast track designation, and priority review, but we may not ultimately
qualify for or benefit from these arrangements.
We may seek various regulatory incentives, such
as EUA, orphan drug exclusivity, breakthrough therapy designation, fast track designation, accelerated approval, priority review and Priority
Review Vouchers (“PRVs”), where available, that provide for certain periods of exclusivity, expedited review and/or other
benefits, and we may also seek similar designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining
whether or not products qualify for such regulatory incentives and benefits. We cannot guarantee that we will be able to receive orphan
drug status from FDA or equivalent regulatory designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy
or fast track designation, which may provide certain potential benefits such as more frequent meetings with FDA to discuss the development
plan, intensive guidance on an efficient drug development program, and potential eligibility for rolling review or priority review. Legislative
developments in the U.S., including proposed legislation that would restrict eligibility for PRVs, may affect our ability to qualify for
these programs in the future.
Even if we are successful in obtaining beneficial
regulatory designations by FDA or other regulatory agency for our product candidates, such designations may not lead to faster development
or regulatory review or approval, and it does not increase the likelihood that our product candidates will receive marketing approval.
We may not be able to obtain or maintain such designations for our product candidates, and our competitors may obtain these designations
for their product candidates, which could impact our ability to develop and commercialize our product candidates or compete with such
competitors, which would adversely impact our business, financial condition or results of operations.
There is a limited amount of information about us upon which
investors can evaluate our product candidates and business prospects, including because we have a limited operating history developing
product candidates, have not yet successfully commercialized any products, and have a relatively small management team.
Our primary focus is developing our proprietary
monoclonal antibody portfolio, which comprises lenzilumab, ifabotuzumab and HGEN005. We are also currently developing our GM-CSF knockout
gene-editing CAR-T platform to create next-generation CAR-T therapies that preserve the benefits of CAR-T therapy while altogether avoiding
its serious and potentially life-threatening side-effects. Our limited operating history developing clinical-stage product candidates
may make it more difficult for us to succeed or for investors to be able to evaluate our business and prospects. In addition, as an early-stage
clinical development company, we have limited experience in development activities, including conducting clinical trials, or seeking and
obtaining regulatory approvals, even though our executives have had relevant experience at other companies. We currently have eleven full-time
employees and therefore are heavily dependent on external consultants and expert vendors for scientific, clinical manufacturing and regulatory
expertise. To execute our business plan we will need to successfully:
|
·
|
execute our product candidate development activities, including successfully completing our clinical trial programs, including our
collaborations and partnerships;
|
|
·
|
obtain required regulatory approvals or authorizations for the development and commercialization of our product candidates;
|
|
·
|
manage our costs and expenses related to clinical trials, regulatory approvals, manufacturing and commercialization;
|
|
·
|
secure substantial additional funding;
|
|
·
|
develop and maintain successful strategic relationships;
|
|
·
|
build and maintain a strong intellectual property portfolio;
|
|
·
|
build and maintain appropriate clinical, sales, manufacturing, distribution, and marketing capabilities on our own or through third
parties; and
|
|
·
|
gain market acceptance and favorable reimbursement status for our product candidates.
|
If we are unsuccessful in accomplishing these
objectives, we may not be able to develop product candidates, raise capital, expand our business, or continue our operations.
In addition to our collaboration with the NIH, IMPACT Partnership
and SAHMRI and the University of Adelaide, we may, in the future, seek to enter into collaborations with other third parties for the discovery,
development and commercialization of our product candidates. If our collaborators cease development efforts under our collaboration agreements,
or if any of those agreements are terminated, these collaborations may fail to lead to commercial products, and we may never receive milestone
payments or future royalties under these agreements.
We may in the future seek to enter into agreements
with other third-party collaborators for research, development and commercialization of other therapeutic technologies or product candidates.
Biopharmaceutical companies are our likely future collaborators for any marketing, distribution, development, licensing, or broader collaboration
arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or at all, or such collaborations are not
successful, we may not be able to execute our strategy to develop our product candidates or therapies that we believe could benefit from
the resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance.
With respect to our existing collaboration agreements,
we have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization
of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators' abilities
to successfully perform the functions assigned to them in these arrangements.
Collaborations involving our product candidates
pose the following risks to us:
|
·
|
collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
|
|
·
|
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development
or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators' strategic focus or
available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;
|
|
·
|
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon
a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
|
|
·
|
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
under terms that are more economically attractive than ours;
|
|
·
|
collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing
and distribution of such product or products;
|
|
·
|
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such
a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to
litigation or potential liability;
|
|
·
|
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
|
|
·
|
disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization
of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and
|
|
·
|
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or
commercialization of the applicable product candidates.
|
As a result of the foregoing, our current and
any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner
or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product
development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize
our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our
business, financial condition, results of operations and prospects.
Moreover, to the extent that any of our existing
or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates,
including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property
rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and
have a material adverse effect on our business, financial condition, results of operations and prospects.
We have relied and may in the future rely on third parties to
conduct ISTs of our products, which is cost-effective for us but affords the investigators the ability to retain significant control over
the design and conduct of the trials, as well as the use of the data generated from their efforts.
We have relied and may in the future rely on third
parties to conduct and sponsor clinical trials relating to lenzilumab, our GM-CSF gene knockout platform and our other immunotherapies,
ifabotuzumab and HGEN005. Such ISTs may provide us with valuable clinical data that can inform our future development strategy
in a cost-efficient manner, but we do not control the design or conduct of the ISTs, and it is possible that the FDA or non-U.S.
regulatory authorities will not view these ISTs as providing adequate support for future clinical trials, whether controlled by us or
third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial
results.
These arrangements provide us limited information
rights with respect to the ISTs, including access to and the ability to use and reference the data, including for our own regulatory
filings, resulting from the ISTs. However, we would not have control over the timing and reporting of the data from ISTs,
nor would we own the data from the ISTs. If we are unable to confirm or replicate the results from the ISTs or if negative results are
obtained, we would likely be further delayed or prevented from advancing further clinical development. Further, if investigators or institutions
breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared
to the first-hand knowledge, we might have gained had the ISTs been sponsored and conducted by us, then our ability to design and conduct
any future clinical trials ourselves may be adversely affected.
If the third parties conducting our clinical trials do not conduct
the trials in accordance with our agreements with them, our ability to pursue our clinical development programs could be delayed or unsuccessful
and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.
We do not have the ability to conduct all aspects
of our preclinical testing or clinical trials ourselves. Therefore, the timing of the initiation and completion of these trials is uncertain
and may occur on substantially different timing from our estimates. We also use CROs to conduct our clinical trials and rely on medical
institutions, clinical investigators, CROs, and consultants to conduct our trials in accordance with our clinical protocols and regulatory
requirements. Our CROs, investigators, and other third parties play a significant role in the conduct of these trials and subsequent collection
and analysis of data.
There is no guarantee that any CROs, investigators,
or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources
to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to
our clinical protocols, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. If
any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in
our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site. In addition, principal
investigators for our clinical trials may serve as scientific advisors or consultants to us from time-to-time and may receive cash or
equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual
conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be jeopardized.
We may experience delays in commencing or conducting our clinical
trials, in receiving data from third parties or in the continuation or completion of clinical testing, which could result in increased
costs to us, delay our ability to generate product candidate revenue or, ultimately, render us unable to complete the development and
commercialization of our product candidates.
We have product candidates in clinical development
and preclinical development. As with most small biotech companies, the risk of failure for our product candidates is high. It is impossible
to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. Before
obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans.
Before we can initiate clinical trials in the
U.S. for any new product candidates, we are required to submit the results of preclinical testing to FDA as part of an IND application,
along with other information including information about product candidate chemistry, manufacturing, and controls and our proposed clinical
trial protocol. For our programs already underway, we are required to report or provide information to appropriate regulatory authorities
in order to continue with our testing programs. If we are unable to make timely regulatory submissions for any of our programs, it will
delay our plans for our clinical trials. If those third parties do not make the required data available to us, we will likely have to
identify and contract with another third party, and/or develop all necessary preclinical and clinical data on our own, which will lead
to significant delays and increase development costs of the product candidate. In addition, FDA may require us to conduct additional preclinical
testing for any product candidate before it allows us to initiate clinical testing under any IND application, which may lead to additional
delays and increase the costs of our preclinical development. Moreover, despite the presence of an active IND application for a product
candidate, clinical trials can be delayed for a variety of reasons, including delays in:
|
·
|
identifying, recruiting, and enrolling qualified subjects to participate in a clinical trial;
|
|
·
|
identifying, recruiting, and training suitable clinical investigators;
|
|
·
|
reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which
can be subject to extensive negotiation, may be subject to modification from time-to-time, and may vary significantly among different
CROs and trial sites;
|
|
·
|
obtaining and maintaining sufficient quantities of a product candidate for use in clinical trials, either as a result of transferring
the manufacturing of a product candidate to another site or manufacturer, deferring ordering or production of product in order to conserve
resources or mitigate risk, having product in inventory become no longer suitable for use in humans, or other reasons that reduce or delay
availability of drug supply;
|
|
·
|
obtaining and maintaining Institutional Review Board (“IRB”) or ethics committee approval to conduct a clinical trial
at an existing or prospective site;
|
|
·
|
retaining or replacing participants who have initiated a clinical trial but may withdraw due to adverse events from the therapy, insufficient
efficacy, fatigue with the clinical trial process, or personal issues;
|
|
·
|
developing any companion diagnostic necessary to ensure the study enrolls the target population;
|
|
·
|
being required by the FDA to add more patients or sites or to conduct additional trials; or
|
|
·
|
the FDA placing a clinical trial on hold.
|
Once
a clinical trial has begun, recruitment and enrollment of subjects may be slower than we anticipate. Numerous companies and institutions
are conducting clinical studies in similar patient populations which can result in competition for qualified patients. In addition, clinical
trials will take longer than we anticipate if we are required, or believe it is necessary, to enroll additional subjects than originally
planned. Clinical trials may also be delayed as a result of ambiguous or negative interim results. Further, a clinical trial may be suspended
or terminated by us, an IRB, an ethics committee, or a data safety monitoring committee overseeing the clinical trial, any of our clinical
trial sites with respect to that site, or FDA or other regulatory authorities, due to several factors, including:
|
·
|
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
|
|
·
|
inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities;
|
|
·
|
inability to provide timely supply of drug product due to shortages or other issues with the drug product;
|
|
·
|
unforeseen safety issues, known safety issues that occur at a greater frequency or severity than we anticipate, or any determination
that the clinical trial presents unacceptable health risks; or
|
|
·
|
lack of adequate funding to continue the clinical trial or unforeseen significant incremental costs related to the trial.
|
Additionally, if any future development partners
do not develop the licensed product candidates in the time and manner that we expect, or at all, the clinical development efforts related
to these licensed product candidates could be delayed or terminated. In addition, our ability to enforce our partners’ obligations
under any future collaboration efforts may be limited due to time and resource constraints, competing corporate priorities of our future
partners, and other factors.
Any delays in the commencement of our clinical
trials may delay or preclude our ability to further develop or pursue regulatory approval for our product candidates. Changes in U.S.
and foreign regulatory requirements and guidance also may occur, and we may need to amend clinical trial protocols to reflect these changes.
Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may affect the costs, timing, and
likelihood of a successful completion of a clinical trial.
If we are required to conduct additional clinical
trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete
clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or do not meet the
standard for acceptability by regulatory authorities or if there are safety concerns, we may:
|
·
|
be delayed in obtaining marketing approval for our product candidates;
|
|
·
|
not obtain marketing approval or EUA at all;
|
|
·
|
obtain approval for indications or patient populations that are not as broad as intended or desired;
|
|
·
|
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
|
|
·
|
be subject to additional post-marketing testing requirements; or
|
|
·
|
have the product removed from the market after obtaining marketing approval.
|
Our product development costs will also increase
if we experience delays in testing or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical
trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change
the design or protocol of one or more of our clinical trials, including to add additional arms or patient populations, which could result
in increased costs and expenses and/or delays. If we or any future development partners experience delays in the completion of, or if
we or any future development partners must terminate, any clinical trial of any product candidate our ability to obtain regulatory approval
for that product candidate will be delayed and the commercial prospects, if any, for the product candidate may suffer as a result. Significant
preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our product candidates and may harm our business and results of operations. In addition, many of these factors may also ultimately lead
to the denial of regulatory approval of a product candidate.
Our product candidates are subject to extensive regulation, compliance
with which is costly and time consuming, may cause unanticipated delays, or may prevent the receipt of the required approvals to commercialize
our product candidates.
The clinical development, approval, manufacturing,
labeling, storage, record-keeping, advertising, promotion, import, export, marketing, and distribution of our product candidates are subject
to extensive regulation by FDA in the U.S. and by comparable authorities in foreign markets. In the U.S., we are not permitted to market
our product candidates until we receive regulatory approval from FDA. The process of obtaining regulatory approval is expensive, often
takes many years, and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target
indications. Approval policies or regulations may change, and FDA has substantial discretion in the drug approval process, including the
ability to delay, limit, or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development
of product candidates, regulatory approval is never guaranteed. FDA or other comparable foreign regulatory authorities can delay, limit,
or deny approval of a product candidate for many reasons, including:
|
·
|
such authorities may disagree with the design or implementation of our or any future development partners’ clinical trials;
|
|
·
|
such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard
of care is potentially different from the U.S.;
|
|
·
|
the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;
|
|
·
|
we or any future development partners may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh
its safety risks;
|
|
·
|
such authorities may disagree with our interpretation of data from preclinical studies or clinical;
|
|
·
|
such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we or
any future development partners contract for clinical and commercial supplies; or
|
|
·
|
the approval policies or regulations of such authorities may significantly change in a manner rendering our or any future development
partners’ clinical data insufficient for approval.
|
With respect to foreign markets, approval procedures
vary widely among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review
periods, and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals
may result in increased caution by FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy
or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or
inability to obtain, applicable regulatory approvals may delay or prevent us or any future development partners from commercializing our
product candidates.
The results of preclinical studies and early clinical trials
are not always predictive of future results. Any product candidate we or any future development partners advance into clinical trials
may not have favorable results in later clinical trials, if any, or receive regulatory approval.
Drug development has substantial inherent risk.
We or any future development partners will be required to demonstrate through adequate and well-controlled clinical trials that our product
candidates are effective, with a favorable benefit-risk profile, for use in their target populations for their intended indications before
we can seek regulatory approvals for their commercial sale. Drug development is a long, expensive and uncertain process, and delay or
failure can occur at any stage of development, including after commencement of any of our clinical trials. Success in early clinical trials
does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate
sufficient safety or efficacy despite having progressed through initial clinical testing. Furthermore, our future trials will need to
demonstrate sufficient safety and efficacy for approval by regulatory authorities in larger patient populations. Companies frequently
suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition,
only a small percentage of drugs under development result in the submission of an NDA or BLA to FDA, and even fewer are approved for commercialization.
In addition, serious adverse or undesirable side
effects may emerge or be identified during later stages of development that were not observed in earlier stages. If our product candidates,
either alone or in combination with other therapeutics, are associated with serious adverse events or undesirable side effects or unacceptable
drug-drug interactions in clinical trials or have characteristics that are unexpected in clinical trials or preclinical testing, we may
need to abandon their development or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable
side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical
development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that
prevent further development of the compound. In addition, if third parties manufacture or use our product candidates without our permission,
and generate adverse events or unacceptable side effects, this could also have an adverse impact on our development efforts.
Unacceptable adverse events caused by any of our
product candidates that we advance into clinical trials could cause us or regulatory authorities to interrupt, delay, or halt clinical
trials and could result in the denial of regulatory approval by FDA or other regulatory authorities for any or all targeted indications
and markets. This in turn could prevent us from completing development or commercializing the affected product candidate and generating
revenue from its sale. We have not yet successfully completed testing of any of our product candidates for the treatment of the indications
for which we intend to seek approval in humans, and we currently do not know the extent of adverse events, if any, that will be observed
in individuals who receive any of our product candidates. If any of our product candidates cause unacceptable adverse events in clinical
trials, we may not be able to obtain regulatory approval or commercialize such product candidates.
We face risks associated with clinical operations abroad,
which may adversely affect our financial condition and results of operations, and we may not be able to receive conditional marketing
approvals for lenzilumab in COVID-19 patients in markets outside the U.S.
The Mexican regulatory agency, COFEPRIS, granted
us permission to expand the Phase 3 study of lenzilumab in patients with COVID-19 in Mexico. We did not open any sites in Mexico or enroll
any patients in that country; however, we may do so in the future. Partners also are conducting or planning to conduct clinical trials
involving lenzilumab in Korea, Australia and the United Kingdom, as well as potentially in other countries in patients with COVID-19 and
other indications. In addition, we are working to seek conditional marketing authorization (“CMA”) for lenzilumab in hospitalized
COVID-19 patients in the European Union and the United Kingdom. We have not received any authorization or approval to sell lenzilumab
in any country but would expect to commence commercial operations, through a partner or on our own, only after such authorization or approval
were received. As with our development programs in the U.S., our product candidates must be approved for marketing and sale by regulatory
authorities in each jurisdiction to which we may apply for approval and, once approved, are subject to extensive regulation by regulatory
agencies in other countries. We anticipate that we may file for marketing approval in additional countries and for additional indications
and products over the next several years. These and any future marketing applications we file may not be approved by the regulatory authorities
on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their
use. We cannot state with certainty when or whether any of our product candidates under development will be approved by any foreign regulators
or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products,
once launched, will be commercially successful.
In addition, operations abroad are accompanied
by certain financial, political, economic and other risks, including those listed below:
|
·
|
Foreign Currency Exchange: Operations internationally may subject us to risks related to foreign currency exchange risks as we make
payments, or incur obligations, denominated in foreign currencies. We cannot predict future fluctuations in the foreign currency exchange
rates of the U.S. dollar. If the U.S. dollar appreciates significantly against certain currencies and our practices do not sufficiently
offset the effects of such appreciation, our results of operations would be adversely affected, and our stock price may decline.
|
|
·
|
Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that will govern our
international operations with respect to payments to government officials. Our international operations would be heavily regulated and
require significant interaction with foreign officials. In certain circumstances, strict compliance with anti-bribery laws may conflict
with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a
manner that is different than local custom. In addition, despite our efforts, our policies and procedures may not protect us from reckless
or criminal acts committed by persons who act on our behalf. Enforcement activities under anti-bribery laws could subject us to administrative
and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from
health care programs.
|
|
·
|
Other risks inherent in conducting foreign operations include:
|
|
o
|
International operations, including any use of third-party manufacturers, distributors, CROs and collaboration arrangements outside
the U.S., expose us to increased risk of theft of our intellectual property and other proprietary technology, particularly in jurisdictions
with less robust intellectual property protections than the U.S., as well as restrictive government actions against our intellectual property
and other foreign assets such as nationalization, expropriation or the imposition of compulsory licenses.
|
|
o
|
We may be subject to protective economic policies taken by foreign governments, such as trade protection measures and import and export
licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the U.S. or other governments.
|
|
o
|
Our foreign operations, third-party manufacturers, CROs or strategic partners could be subject to business interruptions for which
we or they may be uninsured or inadequately insured.
|
|
o
|
Our operations may also be adversely affected if there is political instability or disruption in any other geographic region where
we may have operations, which could impact our ability to do business in those areas.
|
If
we were to encounter any of these risks, our foreign operations may be adversely affected, which could have an adverse effect on our overall
business and results of operations.
If we fail to attract and retain key management and clinical
development personnel, or if the attention of such personnel is diverted, we may be unable to successfully manage our business and develop
or commercialize our product candidates.
We will need to effectively manage our managerial,
operational, financial, and other resources in order to successfully pursue our clinical development and commercialization efforts. As
a company with a limited number of personnel, we are heavily affected by turnover and highly dependent on the expertise of the members
of our senior management, in particular our Chief Executive Officer, Dr. Cameron Durrant, and Dr. Dale Chappell, the controlling owner
of the Black Horse Entities (as defined below), our current Chief Scientific Officer and a director. Furthermore, we rely on third party
consultants for a variety of services. We cannot predict the impact of the loss of such individuals or the loss of services of any of
our other senior management, should they occur, or the difficulty in replacing such individuals. Such losses could delay or prevent the
further development and potential commercialization of our product candidates and, if we are not successful in finding suitable replacements,
could harm our business.
If our competitors develop similar or comparable treatments for
the target indications of our product candidates that are approved more quickly, marketed more successfully or are demonstrated to be
safer or more effective than our product candidates, or if FDA approves generic or biosimilar competitors to our products post-approval,
our commercial opportunity will be reduced or eliminated.
We compete in an industry characterized by rapidly
advancing technologies, intense competition, a changing regulatory and legislative landscape and a strong emphasis on the benefits of
intellectual property protection and regulatory exclusivities. Our competitors include pharmaceutical companies, other biotechnology companies,
academic institutions, government agencies and other private and public research organizations. We compete with these parties in immunotherapy
and oncology treatments and in recruiting highly qualified personnel. Our product candidates, if successfully developed and approved,
may compete with established therapies, with new treatments that may be introduced by our competitors, including competitors relying on
our biologics approvals under section 351(k) of the Public Health Service Act, or with generic copies of our products approved by FDA
under an abbreviated new drug application (“ANDA”), referencing our drug products. We believe that competitors are actively
developing competing products to our product candidates. See “Competition” in the “Business” section of our 2020
Annual Report on Form 10-K for a discussion of competition with respect to our current product candidates.
Many of our competitors and potential competitors
have substantially greater scientific, research, and product development capabilities, as well as greater financial, marketing, sales
and human resources capabilities than we do. In addition, many specialized biotechnology firms have formed collaborations with large,
established companies to support the research, development and commercialization of products that may be competitive with ours. Accordingly,
our competitors may be more successful with respect to their products than we may be in developing, commercializing, and achieving widespread
market acceptance for our products. If a competitor obtains approval for an orphan drug that is the same drug or the same biologic as
one of our candidates before we do, we will be blocked from obtaining FDA approval for seven years from the date of the competitor’s
product, unless we can establish that our product is clinically superior to the previously-approved competitor’s product or we can
meet another exception, such as by showing that the competitor has failed to provide an adequate supply of its product to patients after
approval. In addition, our competitors’ products may be more effective or more effectively marketed and sold than any treatment
we or our development partners may commercialize and may render our product candidates obsolete or non-competitive before we can recover
the expenses related to developing and supporting the commercialization of any of our product candidates. Developments by competitors
may render our product candidates obsolete or noncompetitive. After one of our product candidates is approved, FDA may also approve a
generic version with the same dosage form, safety, strength, route of administration, quality, performance characteristics and intended
use as our product. These generic equivalents would be less costly to bring to market and could generally be offered at lower prices,
thereby limiting our ability to gain or retain market share.
The acquisition or licensing of pharmaceutical
products is also very competitive, and a number of more established companies, which have acknowledged strategies to in-license or acquire
products, may have competitive advantages as may other emerging companies taking similar or different approaches to product acquisitions.
The more established companies may have a competitive advantage over us due to their size, cash flows, institutional experience and historical
corporate reputation.
We are subject to a multitude of manufacturing risks, any of
which could substantially increase our costs and limit supply of our products.
We are wholly dependent on third party contract
manufacturers for the timely supply of adequate quantities of our products which meet or exceed requisite quality and production standards
for use in clinical and nonclinical studies. Given the extensive risks, scope, complexity, cost, regulatory requirements, and commitment
of resources associated with developing the capabilities to manufacture one or more of our products, we have no present plan or intention
of developing in-house manufacturing capabilities for nonclinical, clinical or commercial scale production, beyond our current supervision
and management of our third-party contract manufacturers. In addition, in order to balance risk and conserve financial and human resources,
we have and may continue from time-to-time to defer commitment to production of product, which could result in delays to the continued
progress of our clinical and nonclinical testing.
In addition to the foregoing, the process of manufacturing
our products is complex, highly regulated, and subject to several risks, including but not limited to the following:
|
·
|
We, and our contract manufacturers, must comply with FDA’s current Good Manufacturing Practice, (“cGMP”), regulations
and guidance. We, and our contract manufacturers, may encounter difficulties in achieving quality control and quality assurance and may
experience shortages in qualified personnel. We, and our contract manufacturers, are subject to inspections by FDA and comparable agencies
in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements
or any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our products as a result
of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements, or a failure to
pass any regulatory authority inspection, could significantly impair our ability to develop and commercialize our products, including
leading to significant delays in the availability of products for our clinical studies or the termination or hold on a clinical study,
or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could
also result in the imposition of sanctions, including injunctions, civil penalties, failure of regulatory authorities to grant marketing
approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products,
operating restrictions, adverse publicity, and criminal prosecutions, any of which could damage our reputation. If we are not able to
maintain regulatory compliance, we may not be permitted to market our products and/or may be subject to product recalls, seizures, injunctions,
or criminal prosecution. Any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory
shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. Once our product candidates
are approved, we may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives.
|
|
·
|
The manufacturing facilities in which our products are made could be adversely affected by equipment failures, plant closures, capacity
constraints, competing customer priorities or changes in corporate strategy or priorities, process changes or failures, changes in business
models or operations, materials or labor shortages, natural disasters, power failures and numerous other factors.
|
|
·
|
We are wholly dependent upon third party CMOs for the timely supply of adequate quantities of requisite quality product for our nonclinical,
clinical and, if approved by regulatory authorities, commercial scale production.
|
If any product candidate that we successfully develop does not
achieve broad market acceptance among physicians, patients, healthcare payers and the medical community, the revenue that it generates
may be limited.
Even if our product candidates receive regulatory
approval, they may not gain market acceptance among physicians, patients, healthcare payers, and the medical community. Coverage and reimbursement
of our product candidates by third-party payers, including government payers, generally is also necessary for commercial success. The
degree of market acceptance of any approved product candidates will depend on several factors, including:
|
·
|
the efficacy and safety as demonstrated in clinical trials;
|
|
·
|
the clinical indications for which the product candidate is approved;
|
|
·
|
acceptance by physicians, major operators of hospitals and clinics, and patients of the product candidate as a safe and effective
treatment;
|
|
·
|
the potential and perceived advantages of product candidates over alternative treatments;
|
|
·
|
the safety of product candidates seen in a broader patient group, including its use outside the approved indications;
|
|
·
|
the cost of treatment in relation to alternative treatments;
|
|
·
|
the availability of adequate reimbursement and pricing by payers;
|
|
·
|
relative convenience and ease of administration;
|
|
·
|
the prevalence and severity of adverse events;
|
|
·
|
the effectiveness of our sales and marketing efforts; and
|
|
·
|
the ability to manage any unfavorable publicity relating to the product candidate.
|
If any product candidate is approved but does
not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers, and patients, we may not generate sufficient
revenue from that product candidate and may not become or remain commercially attractive as a standalone indication for that product.
Reimbursement may be limited or unavailable in certain market
segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.
Market acceptance and sales of our product candidates
will depend significantly on the availability of adequate insurance coverage and reimbursement from third-party payers for any of our
product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers,
such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement
levels. Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer’s determination
that use of a product candidate is:
|
·
|
a covered benefit under its health plan;
|
|
·
|
safe, effective, and medically necessary;
|
|
·
|
appropriate for the specific patient;
|
|
·
|
neither experimental nor investigational.
|
Obtaining coverage and reimbursement approval
for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide
supporting scientific, clinical, and cost effectiveness data for the use of our product candidates to the payer. We may not be able to
provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement
will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for,
or the price of, our product candidates. If reimbursement is not available or is available only to limited levels or with restrictions,
we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.
In the U.S. and in certain foreign jurisdictions,
there have been a number of legislative and regulatory changes to the health care system that could affect our ability to sell our product
candidates profitably. In particular, the Medicare Modernization Act of 2003 revised the payment methods for many product candidates under
Medicare. This has resulted in lower rates of reimbursement. There have been numerous other federal and state initiatives designed to
reduce payment for pharmaceuticals.
As a result of legislative proposals and the trend
toward managed health care in the U.S., third-party payers are increasingly attempting to contain health care costs by limiting both coverage
and the level of reimbursement of new drugs. They may also refuse to provide coverage of approved product candidates for medical indications
other than those for which FDA has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party
payers will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs. We could
be subject to pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the
increasing influence of health maintenance organizations, and additional legislative proposals as well as country, regional, or local
healthcare budget limitations. Similar concerns about the costs of treatment have been raised in Europe and the United Kingdom.
Governments may impose price controls, which may adversely affect
our future profitability.
We intend to seek approval to market our future
product candidates in the U.S. and potentially in foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions, we
will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some foreign countries, particularly
in the European Union and the United Kingdom, the pricing of prescription pharmaceuticals and biologics is subject to governmental control.
In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval
for a product candidate. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, we may be unable to achieve or sustain profitability.
We face potential product liability exposure and, if successful
claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.
The use of our product candidates in clinical
trials and the sale of any product candidates for which we may obtain marketing approval expose us to the risk of product liability claims.
Product liability claims may be brought against us or any future development partners by participants enrolled in our clinical trials,
patients, health care providers, or others using, administering, or selling our product candidates. If we cannot successfully defend ourselves
against any such claims, or have insufficient insurance protection, we would incur substantial liabilities. Regardless of merit or eventual
outcome, product liability claims may result in:
|
·
|
withdrawal of clinical trial participants;
|
|
·
|
termination of clinical trial sites or entire trial programs;
|
|
·
|
costs of related litigation;
|
|
·
|
substantial monetary awards to trial participants or other claimants;
|
|
·
|
decreased demand for our product candidates and loss of revenue;
|
|
·
|
impairment of our business reputation;
|
|
·
|
diversion of management and scientific resources from our business operations; and
|
|
·
|
the inability to commercialize our product candidates.
|
We have obtained limited product liability insurance
coverage for our clinical trials domestically and in selected foreign countries where we are conducting clinical trials. As such, our
insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance
coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost
or in sufficient amounts to protect us against losses due to product liability. We intend to expand our insurance coverage for product
candidates to include the sale of commercial products if we obtain marketing approval for our product candidates in development; however,
we may be unable to obtain commercially reasonable product liability insurance for any product candidates approved for marketing. Large
judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability
claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our working capital
and adversely affect our business.
Our employees and consultants may engage in misconduct or other
improper activities, including noncompliance with regulatory standards, which could have a material adverse effect on our business.
We are exposed to the risk of employee fraud or
other misconduct. Misconduct by employees or consultants could include intentional failures to comply with FDA regulations
or similar regulations of comparable foreign regulatory authorities, failure to provide accurate information to FDA or comparable foreign
regulatory authorities, failure to comply with manufacturing standards, failure to comply with federal and state healthcare fraud and
abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, failure
to report financial information or data accurately, violations of anti-bribery laws, or failure to disclose unauthorized activities to
us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Employee or consultant misconduct could also involve the improper use of confidential information
obtained in the course of our business, which could result in civil or criminal legal actions, regulatory sanctions, or serious harm to
our reputation. We have adopted a Code of Business Conduct and Ethics and other corporate policies, but it is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful
in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations,
including the imposition of significant fines or other sanctions.
We may encounter difficulties in managing our growth and expanding
our operations successfully.
As we seek to advance our product candidates through
clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, and sales capabilities, and contract with
third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships
with various development partners, suppliers, and other third parties. Future growth will impose significant added responsibilities on
members of management. Our future financial performance and our ability to commercialize our product candidates and to compete effectively
will depend in part on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts
and clinical trials effectively. We may not be able to accomplish these tasks and our failure to accomplish any of them could prevent
us from successfully growing our company.
We and any future development partners, third-party manufacturers
and suppliers use hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials could be
time consuming or costly.
We and any future development partners, third-party
manufacturers and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous
to human health and safety or the environment. Our operations and the operations of our development partner, third-party manufacturers
and suppliers also produce hazardous waste products. Federal, state, and local laws and regulations govern the use, generation, manufacture,
storage, handling, and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive
and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate
the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste
insurance coverage and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and
fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury we could
be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals
could be suspended.
Healthcare reform measures, when implemented, could hinder or
prevent our commercial success.
There have been, and likely will continue to be,
legislative and regulatory proposals at the federal and state levels directed at broadening the availability of health care and containing
or lowering the overall cost of health care. We cannot predict the initiatives that may be adopted in the future. The continuing efforts
of the government, insurance companies, managed care organizations, and other payers of healthcare services to contain or reduce costs
of health care may adversely affect:
|
·
|
the demand for any drug products for which we may obtain regulatory approval;
|
|
·
|
our ability to set a price that we believe is fair for our product candidates;
|
|
·
|
our ability to gain reimbursement at commercially acceptable levels;
|
|
·
|
our ability to generate revenue and achieve or maintain profitability;
|
|
·
|
the level of taxes that we are required to pay; and
|
|
·
|
the availability of capital.
|
We and any of our future development partners will be required
to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to
do so would result in sanctions that would materially harm our business.
If we and any future development partners are
successful in commercializing our products, FDA and foreign regulatory authorities would require that we and any future development partners
report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The
timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event.
We and any future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any
future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not
reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If
we and any future development partners fail to comply with our reporting obligations, FDA or a foreign regulatory authority could take
action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance
of future products.
Our product candidates for which we intend to seek approval as
biologic products may face competition sooner than anticipated.
With the enactment of the Biologics Price Competition
and Innovation Act of 2009, or the BPCIA, as part of the Affordable Care Act, an abbreviated pathway for the approval of biosimilar and
interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for FDA to review and
approve biosimilar biologics, including the possible designation of a biosimilar as ‘‘interchangeable’’ based
on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by FDA until
12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented
by FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes
intended to implement BPCIA may be fully adopted by FDA, any such processes could have a material adverse effect on the future commercial
prospects for our biological products.
We believe that any of our product candidates,
such as lenzilumab, ifabotuzumab and/or HGEN005, if approved as biological products under a BLA, should qualify for the 12-year period
of exclusivity. However, there is a risk that FDA will not consider our product candidates to be reference products for competing products,
potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once
approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Finally, there
is a risk that the 12-year exclusivity period could be reduced which could negatively affect our products.
In addition, foreign regulatory authorities may
also provide for exclusivity periods for approved biological products. For example, biological products in Europe may be eligible for
a 10-year period of exclusivity. However, biosimilar products have been approved under a sub-pathway of the centralized procedure since
2006. The pathway allows sponsors of a biosimilar product to seek and obtain regulatory approval based in part on the clinical trial data
of an originator product to which the biosimilar product has been demonstrated to be ‘‘similar.’’ In many cases,
this allows biosimilar products to be brought to market without conducting the full suite of clinical trials typically required of originators.
It is unclear whether we and our development partner would face competition to our products in European markets sooner than anticipated.
We may in the future be subject to various U.S. federal and state
laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations
by us of such laws could result in fines or other penalties.
If one or more of our product candidates is approved,
we will likely be subject to the various U.S. federal and state laws intended to prevent health care fraud and abuse. The federal anti-kickback
statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products
or services that would be paid for in whole or part by Medicare, Medicaid, or other federal health care programs. Remuneration has been
broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. Many states
have similar laws that apply to their state health care programs as well as private payers. Violations of the anti-kickback laws can result
in exclusion from federal health care programs and substantial civil and criminal penalties.
The False Claims Act imposes liability on persons
who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The
False Claims Act has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services
not provided as claimed, or for services that are not medically necessary. The False Claims Act includes a whistleblower provision that
allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. If our
marketing or other arrangements were determined to violate the False Claims Act or anti-kickback or related laws, then our revenue could
be adversely affected, which would likely harm our business, financial condition, and results of operations.
State and federal authorities have aggressively
targeted medical technology companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts
with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional
practices. Companies targeted in such prosecutions have paid substantial fines in the hundreds of millions of dollars or more, have been
forced to implement extensive corrective action plans or corporate integrity agreements, and have often become subject to consent decrees
severely restricting the manner in which they conduct their business. If we become the target of such an investigation or prosecution
based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar
sanctions, which would materially harm our business.
Also, the Foreign Corrupt Practices Act and similar
worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials
for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect
us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators, or agents. Violations of
these laws, or allegations of such violations, could result in fines, penalties, or prosecution and have a negative impact on our business,
results of operations and reputation.
Legislative or regulatory healthcare reforms in the U.S. may
make it more difficult and costly for us to obtain regulatory approval of our product candidates and to produce, market, and distribute
our products after approval is obtained.
From time-to-time, legislation is drafted and
introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture, and marketing
of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by FDA
in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing
regulations may impose additional costs or lengthen review times of our current product candidates or any future product candidates. We
cannot determine what effect changes in regulations, statutes, legal interpretation, or policies, when and if promulgated, enacted or
adopted may have on our business in the future. Such changes could, among other things, require:
|
·
|
changes to manufacturing methods;
|
|
·
|
additional studies, including clinical studies;
|
|
·
|
recall, replacement, or discontinuance of one or more of our products; and
|
|
·
|
additional record-keeping.
|
Each of these would likely entail substantial
time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive
regulatory approvals for any future products would harm our business, financial condition, and results of operations.
Even if we are able to obtain regulatory approval for our product
candidates, we will continue to be subject to ongoing and extensive regulatory requirements, and our failure to comply with these requirements
could substantially harm our business.
If we receive regulatory approval for our product
candidates, we will be subject to ongoing FDA obligations and continued regulatory oversight and review, such as continued safety reporting
requirements, and we may also be subject to additional FDA post-marketing obligations. If we are not able to maintain regulatory compliance,
we may not be permitted to market our product candidates and/or may be subject to product recalls or seizures.
If the FDA approves any of our product candidates,
the labeling, manufacturing, packaging, storage, distribution, export, adverse event reporting, advertising, promotion and record-keeping
for our products will be subject to extensive regulatory requirements. Violations of these regulatory requirements or the subsequent discovery
of previously unknown problems with the products, including adverse events of unanticipated severity or frequency, may result in:
|
·
|
the issuance of warning or untitled letters;
|
|
·
|
requirements to conduct post-marking clinical trials;
|
|
·
|
restrictions on the marketing and distribution of the product, including potential withdrawal of the product from the market;
|
|
·
|
suspension of ongoing clinical trials;
|
|
·
|
the issuance of product recalls, import and export restrictions, seizures, and detentions; and
|
|
·
|
the issuance of injunctions, or imposition of other civil and/or criminal penalties.
|
Our ability to utilize our net operating loss carryforwards and
certain other tax attributes may be subject to certain limitations.
We have incurred substantial losses during our
history and do not expect to become profitable in the foreseeable future and may never achieve profitability. To the extent that we continue
to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire.
We may be unable to use these losses to offset income before such unused losses expire. The Tax Cuts and Jobs Act, enacted in 2017, limited
the use of net operating loss carryforwards for periods beginning after 2017 to eighty percent of taxable income in the period to which
the losses were carried. However, this limitation on the use of the carryforwards was eliminated by the Coronavirus Aid, Relief and Economic
Security Act (the “CARES” Act) for tax years beginning before January 1, 2021. In addition, Section 382 of the Internal Revenue
Code of 1986, as amended, may limit the utilization of net operating loss carryforwards. Under Section 382, if a corporation undergoes
an ‘‘ownership change’’ (generally defined as a greater than 50% change (by value) in its equity ownership over
a three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax
attributes to offset its post-change income may be limited. We have recently and in the past experienced ownership changes that have resulted
in limitations on the use of a portion of our net operating loss carryforwards. If we experience further ownership changes our ability
to utilize our net operating loss carryforwards could be further limited.
We rely completely on third parties to supply drug substance
and manufacture drug product for our clinical trials and preclinical studies and intend to rely on other third parties to produce commercial
supplies of product candidates, and our dependence on third parties could adversely impact our business.
We are dependent on third-party suppliers. We
regularly evaluate potential alternate sources of supply of raw materials, various components used in production, drug substance and drug
product, but there can be no assurance that any such suppliers would be available, acceptable, or successful. The costs of manufacturing
our drug candidates are high, and we will require additional capital to ensure that we can maintain an adequate supply to conduct our
contemplated development programs.
If our third-party suppliers do not supply sufficient
quantities for product candidates to us on a timely basis and in accordance with applicable specifications and other regulatory requirements,
there could be a significant interruption of our supplies, which would adversely affect clinical development of the product candidate,
including affecting our ability to enroll in and timely progress clinical trials. Furthermore, if any of our contract manufacturers cannot
successfully manufacture material that conforms to our specifications and with regulatory requirements, we will not be able to secure
and/or maintain regulatory approval, if any, for our product candidates.
We will also rely on our contract manufacturers
to purchase from third-party suppliers the materials necessary to produce our product candidates for our anticipated clinical trials.
There are a small number of suppliers for certain capital equipment and raw materials used to manufacture our product candidates. We do
not have any control over the process or timing of the acquisition of these raw materials by our contract manufacturers. Moreover, we
currently do not have agreements in place for the commercial production of these raw materials. Any significant delay in the supply of
a product candidate or the raw material components thereof for an ongoing clinical trial could considerably delay completion of that clinical
trial, product candidate testing, and potential regulatory approval of that product candidate.
We do not expect to have the resources or capacity
to commercially manufacture any of our proposed product candidates, if approved, and will likely continue to be dependent on third-party
manufacturers. Our dependence on third parties to manufacture and supply us with clinical trial materials and any approved product candidates
may adversely affect our ability to develop and commercialize our product candidates on a timely basis.
We may not be successful in establishing and maintaining development
partnerships and licensing agreements, which could adversely affect our ability to develop and commercialize product candidates.
Part of our strategy is to enter into development
partnerships and licensing agreements. We face significant competition in seeking appropriate partners and the negotiation process is
time consuming and complex. Even if we are successful in securing a development partnership, we may not be able to continue it. Moreover,
we may not be successful in our efforts to establish a development partnership or other alternative arrangements for any of our other
existing or future product candidates and programs because, among other reasons, our research and development pipeline may be insufficient,
our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and/or third parties
may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are
successful in our efforts to establish new development partnerships, the terms that we agree upon may not be favorable to us and we may
not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales
of an approved product candidate are disappointing. Any delay in entering into new development partnership agreements related to our product
candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach
the market.
Moreover, if we fail to establish and maintain
additional development partnerships related to our product candidates:
|
·
|
the development of our current or future product candidates may be terminated or delayed;
|
|
·
|
our cash expenditures related to development of certain of our current or future product candidates would increase significantly and
we may need to seek additional financing;
|
|
·
|
we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we
have not budgeted; and
|
|
·
|
we will bear all of the risk related to the development of any such product candidates.
|
Our or any new partner’s failure to develop,
manufacture or effectively commercialize our product would result in a material adverse effect on our business and results of operations
and would likely cause our stock price to decline.
Currently pending, threatened or future litigation or governmental
proceedings or inquiries could result in material adverse consequences, including judgments or settlements.
We are, or may from time-to-time become, involved
in lawsuits and other legal or governmental proceedings. See Note 10 to the Condensed Consolidated Financial Statements included in this
Quarterly Report on Form 10-Q for information regarding currently pending litigation that could have a material impact on the Company.
Many of these matters raise complicated factual and legal issues and are subject to uncertainties and complexities, all of which make
the matters costly to address. The timing of the final resolutions to any such lawsuits, inquiries, and other legal proceedings is uncertain.
Additionally, the possible outcomes or resolutions
to these matters could include adverse judgments or settlements, either of which could require substantial payments, adversely affecting
our consolidated financial condition, results of operations and cash flows. Any judgment against us, the entry into any settlement agreement,
or the imposition of any fine could have a material adverse effect on our consolidated financial condition, results of operations and
cash flows.
The terms of our loan agreement with Hercules may restrict our
current and future operations, particularly our ability to respond to changes in business or to take certain actions, including to pay
dividends to our stockholders.
On March 10, 2021, we entered into the Loan and Security Agreement
with Hercules Capital, Inc. (the “Term Loan”). As of March 31, 2021, we had approximately $24.4 million of accrued debt under
the Term Loan. The Term Loan has a scheduled maturity date of March 1, 2025 and is secured by a first priority security interest in substantially
all of our assets. The Term Loan contains, and any future indebtedness we incur will likely contain, a number of restrictive covenants
that impose operating restrictions, including restrictions on our ability to engage in acts that may be in our best long-term interests.
The Term Loan includes covenants that, among other things, restrict our ability to (i) declare dividends or redeem or repurchase equity
interests; (ii) incur additional liens; (iii) make loans and investments; (iv) incur additional indebtedness; (v) engage in mergers, acquisitions,
and asset sales; (vi) transact with affiliates; (vii) undergo a change in control; (viii) add or change business locations; and (ix) engage
in businesses that are not related to our existing business. The Term Loan also requires that we at all times maintain unrestricted cash
of not less than $10.0 million, which amount may be increased to $20.0 million if we borrow the second tranche of the Term Loan.
A breach of any of these covenants could result in an event of default
under the Loan Agreement. Upon the occurrence of such an event of default, Hercules may, at its discretion, accelerate and demand payment
of all or any part of the outstanding advances, together with a prepayment charge, end of term charge, and all interest due and payable
under the Term Loan. Hercules also may seek to realize on the collateral we have pledged as security for the Term Loan. If our indebtedness
is accelerated, we cannot assure you that we will have sufficient assets to repay the indebtedness. The restrictions and covenants in
the Term Loan and any future financing agreements may adversely affect our ability to finance future operations or capital needs or to
engage in other business activities.
Future acquisitions of and investments in new businesses could
impact our business and financial condition.
From time-to-time, we may acquire or invest in
businesses or partnerships that we believe could complement our business and drug candidates. The pursuit of such acquisitions or investments
may divert the attention of management and cause us to incur various expenses, regardless of whether the acquisition or investment is
ultimately completed. In addition, acquisitions and investments may not perform as expected and we may be unable to realize the expected
benefits, synergies, or developments that we may initially anticipate. Further, if we are able to successfully identify and acquire additional
businesses, we may not be able to successfully integrate the acquired personnel or operations, or effectively manage the combined business
following the acquisition, any of which could harm our business and financial condition.
In addition, to the extent we finance any acquisition
or investment in cash, it would reduce our cash reserves, and to the extent the purchase price is paid with shares of our common or preferred
stock, it could be dilutive to our current stockholders. To the extent we finance any acquisition or investment with the proceeds from
the incurrence of debt, this would increase our level of indebtedness and could negatively affect our liquidity, credit rating and restrict
our operations. Moreover, we may face contingent liabilities in connection with any acquisitions or investments.
Risks Related to Intellectual Property
If we fail to adequately protect or enforce our intellectual
property rights or secure rights to patents of others, the value of our intellectual property rights would diminish, and our business
and competitive position would suffer.
Our success, competitive position and future revenues
will depend in part on our ability and the abilities of our licensors and licensees to obtain and maintain patent protection for our products,
methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary
rights and to operate without infringing the proprietary rights of third parties. We have an active patent protection program that includes
filing patent applications on new compounds, formulations, delivery systems and methods of making and using products and prosecuting these
patent applications in the U.S. and abroad. As patents issue, we also file continuation applications as appropriate. Although we have
taken steps to build what we believe to be a strong patent portfolio, we cannot predict:
|
·
|
the degree and range of protection any patents will afford us against competitors, including whether third parties find ways to invalidate
or otherwise circumvent our licensed patents;
|
|
·
|
if and when patents will issue in the U.S. or any other country;
|
|
·
|
whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications;
|
|
·
|
whether we will need to initiate litigation or administrative proceedings to protect our intellectual property rights, which may be
costly whether we win or lose;
|
|
·
|
whether any of our patents will be challenged by our competitors alleging invalidity or unenforceability and, if opposed or litigated,
the outcome of any administrative or court action as to patent validity, enforceability or scope;
|
|
·
|
whether a competitor will develop a similar compound that is outside the scope of protection afforded by a patent or whether the patent
scope is inherent in the claims modified due to interpretation of claim scope by a court;
|
|
·
|
whether there were activities previously undertaken by a licensor that could limit the scope, validity or enforceability of licensed
patents and intellectual property; or
|
|
·
|
whether a competitor will assert infringement of its patents or intellectual property, whether or not meritorious, and what the outcome
of any related litigation or challenge may be.
|
Our success also depends upon the skills, knowledge
and experience of our scientific and technical personnel, our consultants and advisors as well as our licensors, sublicensees and contractors.
To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade
secret protection and confidentiality agreements. To this end, we require all employees, consultants and board members to enter into agreements
that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas,
developments, discoveries and inventions important to our business. These agreements may not provide adequate protection for our trade
secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others
of such information. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets,
know-how and other proprietary rights would be significantly impaired, and our business and competitive position would suffer.
Due to legal and factual uncertainties regarding the scope and
protection afforded by patents and other proprietary rights, we may not have meaningful protection from competition.
Our long-term success will substantially depend
upon our ability to protect our proprietary technologies from infringement, misappropriation, discovery and duplication and avoid infringing
the proprietary rights of others. Our patent rights, and the patent rights of biopharmaceutical companies in general, are highly uncertain
and include complex legal and factual issues. These uncertainties also mean that any patents that we own or may obtain in the future could
be subject to challenge, and even if not challenged, may not provide us with meaningful protection from competition. Patents already issued
to us or our pending applications may become subject to dispute, and any dispute could be resolved against us.
If some or all of our or any licensor’s patents expire
or are invalidated or are found to be unenforceable, or if some or all of our patent applications do not result in issued patents or result
in patents with narrow, overbroad, or unenforceable claims, or claims that are not supported in regard to written description or enablement
by the specification, or if we are prevented from asserting that the claims of an issued patent cover a product of a third party, we may
be subject to competition from third parties with products in the same class of products as our product candidates or products with the
same active pharmaceutical ingredients as our product candidates, including in those jurisdictions in which we have no patent protection.
Our commercial success will depend in part on
obtaining and maintaining patent and trade secret protection for our product candidates, as well as the methods for treating patients
in the product indications using these product candidates. We will be able to protect our product candidates and the methods for treating
patients in the applicable product indications using these product candidates from unauthorized use by third parties only to the extent
that we or our exclusive licensor owns or controls such valid and enforceable patents or trade secrets.
Even if our product candidates and the methods
for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and have
claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a limited amount
of time. Our and any licensor’s ability to obtain patents can be highly uncertain and involve complex and in some cases unsettled
legal issues and factual questions. Furthermore, different countries have different procedures for obtaining patents, and patents issued
in different countries provide different degrees of protection against the use of a patented invention by others. Therefore, if the issuance
to us or any licensor, in a given country, of a patent covering an invention is not followed by the issuance, in other countries, of patents
covering the same invention, or if any judicial interpretation of the validity, enforceability, or scope of the claims in, or the utility,
written description or enablement in, a patent issued in one country is not similar to the interpretation given to the corresponding patent
issued in another country, our ability to protect our intellectual property in those countries may be limited. Changes in either patent
laws or in interpretations of patent laws in the U.S. and other countries may materially diminish the value of our intellectual property
or narrow the scope of our patent protection.
We may be subject to competition from third parties
with products in the same class of products as our product candidates, or products with the same active pharmaceutical ingredients as
our product candidates in those jurisdictions in which we have no patent protection. Even if patents are issued to us or any licensor
regarding our product or methods of using them, those patents can be challenged by our competitors who can argue such patents are invalid
or unenforceable on a variety of grounds, including lack of utility, lack sufficient written description or enablement, utility, or that
the claims of the issued patents should be limited or narrowly construed. Patents also will not protect our product candidates if competitors
devise ways of making or using these products without legally infringing our patents. The current U.S. regulatory environment may have
the effect of encouraging companies to challenge branded drug patents or to create non-infringing versions of a patented product in order
to facilitate the approval of ANDAs for generic substitutes. These same types of incentives encourage competitors to submit NDAs that
rely on literature and clinical data not prepared for or by the drug sponsor, providing another less burdensome pathway to approval.
If we infringe the rights of third parties, we could be prevented
from selling products and be forced to defend against litigation and pay damages.
There is a risk that we may be inadvertently infringing
the proprietary rights of third parties because numerous U.S. and foreign issued patents and pending patent applications, which are owned
by third parties, exist in the fields that are the focus of our development and manufacturing efforts. Others might have been the first
to make the inventions covered by each of our or any licensor’s pending patent applications and issued patents and/or might have
been the first to file patent applications for these inventions. In addition, because patent applications take many months to publish
and patent applications can take many years to issue, there may be currently pending applications, unknown to us or any licensor, which
may later result in issued patents that cover the production, manufacture, synthesis, commercialization, formulation or use of our product
candidates. In addition, the production, manufacture, synthesis, commercialization, formulation or use of our product candidates may infringe
existing patents of which we are not aware. Defending ourselves against third-party claims, including litigation in particular, would
be costly and time consuming and would divert management’s attention from our business, which could lead to delays in our development
or commercialization efforts. If third parties are successful in their claims, we might have to pay substantial damages or take other
actions that are adverse to our business.
If our products, methods, processes and other
technologies infringe the proprietary rights of other parties, we could incur substantial costs and may have to:
|
·
|
obtain licenses, which may not be available on commercially reasonable terms, if at all;
|
|
·
|
redesign our products or processes to avoid infringement, which may not be possible or could require substantial funds and time;
|
|
·
|
stop using the subject matter claimed in patents held by others, which could cause us to lose the use of one or more of our drug candidates;
|
|
·
|
pay damages royalties, or other amounts; or
|
|
·
|
grant a cross license to our patents to another patent holder.
|
We expect that, as our drug candidates move further
into clinical trials and commercialization and our public profile is raised, we will be more likely to be subject to such claims.
We may fail to comply with any of our obligations under existing
agreements pursuant to which we license or have otherwise acquired rights or technology, which could result in the loss of rights or technology
that are material to our business.
We are a party to technology licenses and have
acquired certain assets and rights that are important to our business and we may enter into additional licenses or acquire additional
assets and rights in the future. We currently hold licenses from Ludwig Institute for Cancer Research (“LICR”), BioWa, Inc.
(“BioWa”), Lonza Sales AG (“Lonza”) Mayo Foundation (“Mayo”) and the University of Zurich (“UZH”).
These licenses impose various commercial, contingent payments, royalty, insurance, indemnification, and other obligations on us. If we
fail to comply with these obligations, the licensor may have the right to terminate the license or take back rights or assets, in which
event we would lose valuable rights under our collaboration agreements, potential claims and our ability to develop product candidates.
We may be subject to claims that our consultants or independent
contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us.
As is common in the biotechnology and pharmaceutical
industry, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants were
previously employed at or may have previously or may be currently providing consulting services to, other biotechnology or pharmaceutical
companies including our competitors or potential competitors. We may become subject to claims that our company or a consultant inadvertently
or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients.
Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could
result in substantial costs and be a distraction to our management team.
We may not be able to protect our intellectual property rights
throughout the world.
Filing, prosecuting and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and we intend to seek patent protection only in selected
countries. Our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling
or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories
where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating
to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products
in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted
narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail
in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our
efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from
the intellectual property that we develop or license.
Risks Related to Our Common Stock
A significant portion of our total outstanding shares are eligible
to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our
business is doing well.
Sales of a substantial number of shares of our
common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell shares,
could depress the market price of our common stock and could impair our future ability to obtain capital, especially through an offering
of equity securities. In addition, holders of a substantial number of shares of our common stock have rights, subject to certain conditions,
to require us to file registration statements covering their shares or to include their shares in registration statements that we may
file for ourselves or other stockholders.
We also have registered all shares of common stock
that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely
sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional
shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.
We have also entered into a Controlled Equity
OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., under which we may issue and
sell from time-to-time shares of common stock having an aggregate gross sales price of up to $100 million through Cantor Fitzgerald, as
sales agent. Through March 31, 2021, we issued and sold 1,796,858 shares of its common stock under the Sales Agreement for net proceeds
of $36.1 million. While we have committed that we will not make any sales of our securities pursuant to the Sales Agreement, unless and
until a new prospectus supplement or a new registration statement is filed, the Sales Agreement remains in full force and effect. Sales
of a substantial number of shares under the Sales Agreement, or the perception that those sales may occur, could cause the market price
of our common stock to decline.
Further, certain shares of our common stock that
are currently outstanding but have not been registered for resale may currently be sold under Rule 144 under the Securities Act or the
Securities Act. Sales of a substantial number of these shares in the public market, or the perception that those sales may occur, could
cause the market price of our common stock to decline.
Our executive officers, directors and principal stockholders,
if they choose to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for
approval, and this concentration of ownership may contribute to volatility in our stock price.
We have a relatively small public float due to
the ownership percentage of our executive officers and directors, and greater than 5% stockholders. Our directors, executive officers,
and the other holders of more than 5% of our common stock together with their affiliates beneficially owned approximately 27.3% of our
common stock as of April 16, 2021.
Some of these persons or entities may have interests
that are different from our other stockholders, which could prevent or discourage unsolicited acquisition proposals or offers for our
common stock that may be in the best interest of our other stockholders. This may also adversely affect the trading price of our common
stock because investors may perceive disadvantages in owning stock in companies with a significant concentration of ownership.
As a result of our small public float, our common
stock may be less liquid, experience reduced daily trading volume and have greater stock price volatility than the common stock of companies
with broader public ownership. In addition, the trading of a relatively small volume of shares of our common stock may result in significant
volatility in our stock price. If and to the extent ownership of our common stock becomes more concentrated, whether due to increased
ownership by our directors and executive officers or other principal stockholders, or other factors, our public float would further decrease,
which in turn would likely result in increased stock price volatility.
Additionally, because a large amount of our stock
is closely held, we may experience low trading volume or large fluctuations in share price and volume due to sales by our principal stockholders.
If our existing stockholders, particularly our directors, executive officers and the holders of more than 5% of our common stock, or their
affiliates or associates, sell substantial amounts of our common stock in the public market, or are perceived by the public market as
intending to sell substantial amounts of our common stock, the trading price of our common stock could decline significantly.
Despite our listing on the Nasdaq Capital Market, there can be
no assurance that an active trading market for our common stock will develop or be sustained, and the Nasdaq Capital Market may subsequently
delist our common stock if we fail to comply with ongoing listing standards.
On September 18, 2020, our common stock commenced
trading on the Nasdaq Capital Market under the symbol “HGEN.” The Nasdaq Capital Market’s rules for listed companies
will require us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the
listing of our common stock. To satisfy the initial listing standards for the Nasdaq Capital Market, we have had to execute a reverse
stock split. In addition to specific listing and maintenance standards, the Nasdaq Capital Market has broad discretionary authority over
the continued listing of securities, which it could exercise with respect to the listing of our common stock.
As a listed company, we are required to meet the
continued listing requirements applicable to all Nasdaq Capital Market companies. If we fail to meet those standards, as applied by Nasdaq
in its discretion, our common stock may be subject to delisting. We intend to take all commercially reasonable actions to maintain our
Nasdaq listing. If our common stock is delisted in the future, it is not likely that we will be able to list our common stock on another
national securities exchange and, as a result, we expect our securities would be quoted on an over-the-counter market; however, if this
were to occur, our stockholders could face significant material adverse consequences, including limited availability of market quotations
for our common stock and reduced liquidity for the trading of our securities. In addition, in the event of such delisting, we could experience
a decreased ability to issue additional securities and obtain additional financing in the future.
The National Securities Markets Improvement Act
of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred
to as “covered securities.” Because our common stock is listed on Nasdaq, shares of our common stock qualify as covered securities
under the statute. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states
to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate
or bar the sale of covered securities in a particular case. Further, if we were no longer listed on Nasdaq, our securities would not qualify
as covered securities under the statute, and we would be subject to regulation in each state in which we offer our securities.
Further, there can be no assurance that an active
trading market for our common stock will be sustained despite our listing on the Nasdaq Capital Market.
Raising additional funds by issuing securities or through licensing
or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary
rights.
To the extent that we raise additional capital
by issuing equity securities, the share ownership of existing stockholders will be diluted. To the extent that additional capital is raised
through the sale of equity or convertible debt securities, the issuance could result in further dilution to our stockholders by causing
a reduction in their proportionate ownership and voting power.
Any future debt financing may involve covenants
that restrict our operations, including, among other restrictions, limitations on our ability to incur liens or additional debt, pay dividends,
redeem our stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. In addition, if we
raise additional funds through licensing arrangements, it may be necessary to grant potentially valuable rights to our product candidates
or grant licenses on terms that are not favorable to us.
Any material weaknesses in our internal control over financing
reporting that we may identify in the future could adversely affect investor confidence, impair the value of our common stock and increase
our cost of raising capital.
If we were to identify any material weaknesses
or significant deficiencies in our internal controls over financial reporting in the future, our operating results might be harmed, we
may fail to meet our reporting obligations or fail to prevent or detect material misstatements in our financial statements. Any such failure
could, in turn, affect the future ability of our management to certify that internal control over our financial reporting is effective.
Inferior internal control over financial reporting could also subject us to the scrutiny of the SEC and other regulatory bodies which
could cause investors to lose confidence in our reported financial information and could subject us to civil or criminal penalties or
stockholder litigation, which could have an adverse effect on our results of operations and the market price of our common stock.
In addition, if we or our independent registered
public accounting firm identify deficiencies in our internal control over financial reporting, the disclosure of that fact, even if quickly
remedied, could reduce the market’s confidence in our financial statements and harm our share price. Furthermore, deficiencies could
result in future non-compliance with Section 404 of the Sarbanes-Oxley Act of 2002. Such non-compliance could subject us to a variety
of administrative sanctions, including review by the SEC or other regulatory authorities.
Our stock price is volatile and purchasers of our common stock
could incur substantial losses.
The market price of our common stock may fluctuate
significantly in response to a number of factors. These factors include those discussed in this “Risk Factors” section of
this Quarterly Report and others such as:
|
·
|
the U.S. Government ending the National Emergency declared for the COVID-19 pandemic;
|
|
·
|
delay or failure in initiating or completing preclinical studies or clinical trials, or unsatisfactory results of these trials and
the resulting impact on ongoing product development;
|
|
·
|
the success, progress, timing and costs of our efforts to evaluate or consummate various strategic alternatives if in the best interests
of our stockholders;
|
|
·
|
our ability to maintain the listing of our common stock on the Nasdaq Capital Market;
|
|
·
|
announcements regarding equity or debt financing transactions;
|
|
·
|
sales or potential sales of substantial amounts of our common stock or securities convertible into our common stock;
|
|
·
|
announcements or social media comments about us or about our competitors including clinical trial results, regulatory approvals, or
new product candidate introductions;
|
|
·
|
developments concerning our development partner, licensors or product candidate manufacturers;
|
|
·
|
litigation and other developments relating to our patents or other proprietary rights or those of our competitors;
|
|
·
|
conditions in the pharmaceutical or biotechnology industries and the economy as a whole;
|
|
·
|
governmental regulation and legislation;
|
|
·
|
recruitment or departure of members of our board of directors, management team or other key personnel;
|
|
·
|
changes in our operating results;
|
|
·
|
any financial projections we may provide to the public, any changes in these projections, our failure to meet these projections, or
changes in recommendations by any securities analysts that elect to follow our common stock;
|
|
·
|
change in securities analysts’ estimates of our performance, or our failure to meet analysts’ expectations; and
|
|
·
|
price and volume fluctuations in the overall stock market or resulting from inconsistent trading volume levels of our shares.
|
In recent years, the stock market in general,
and the market for pharmaceutical and biotechnological companies in particular, has experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing
those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless
of our actual operating performance.
In addition, public statements by us, government
agencies, traditional and social media or others relating to the COVID-19 pandemic (including currently authorized or approved vaccines
and therapeutics and efforts to develop additional COVID-19 vaccines, treatments or therapies) have in the past resulted, and may in the
future result, in significant fluctuations in our stock price. Given the global focus on the COVID-19 pandemic, any information in the
public arena on this topic, whether or not accurate, could have an outsized impact (either positive or negative) on our stock price. Information
related to progress towards our EUA or BLA, the ACTIV-5/BET-B trial or any other studies, or our development, manufacturing and distribution
efforts with respect to lenzilumab, or information regarding such efforts by competitors, may also impact our stock price.
We have never paid and do not intend to pay cash dividends and,
consequently, the ability to achieve a return on any investment in our common stock will depend on appreciation in the price of our common
stock.
We have never paid cash dividends on any of our
capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our business. Therefore,
a holder of our stock is not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to
pay dividends, the ability to receive a return on an investment in our common stock will depend on any future appreciation in the market
value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which it was purchased.
Anti-takeover provisions in our charter documents and Delaware
law, could discourage, delay, or prevent a change in control of our company and may affect the trading price of our common stock.
We are a Delaware corporation, and the anti-takeover
provisions of the Delaware General Corporation Law may discourage, delay, or prevent a change in control by prohibiting us from engaging
in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder,
even if a change in control would be beneficial to our existing stockholders.
Our Amended and Restated Certificate of Incorporation,
as amended (the “Charter”), and our Second Amended and Restated Bylaws (the “Bylaws”) may discourage, delay, or
prevent a change in our management or control over us that stockholders may consider favorable. Our Charter and Bylaws:
|
·
|
provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of
directors then in office;
|
|
·
|
do not provide stockholders with the ability to cumulate their votes; and
|
|
·
|
require advance notification of stockholder nominations and proposals.
|
In addition, our Charter permits the Board to
issue up to 25 million shares of preferred stock with such powers, rights, terms and conditions as may be designated by the Board upon
the issuance of shares of preferred stock at one or more times in the future. Specifically, the Charter permits the Board to approve the
future issuance of all or any shares of the preferred stock in one or more series, to determine the number of shares constituting any
series and to determine any voting powers, conversion rights, dividend rights, and other designations, preferences, limitations, restrictions
and rights relating to such shares without any further authorization by our stockholders. The Board’s power to issue preferred stock
could have the effect of delaying, deterring or preventing a transaction or a change in control of our company that might otherwise be
in the best interest of our stockholders.
General Risk Factors
Our internal computer systems, or those of our third-party vendors,
collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of
our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information,
potentially exposing us to liability or otherwise adversely affecting our business.
Our internal computer systems and those of our
current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to damage or interruption
from computer viruses, computer hackers, malicious code, employee theft or misuse, denial-of-service attacks, sophisticated nation-state
and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
While we seek to protect our information technology systems from system failure, accident and security breach, if such an event were to
occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations,
whether due to a loss of our trade secrets or other proprietary information or other disruptions. For example, the loss of clinical trial
data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated
with the investigation, remediation and potential notification of the breach to counterparties and data subjects could be material. In
addition, our remediation efforts may not be successful. If we do not allocate and effectively manage the resources necessary to build
and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction
errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property
or other proprietary information.
To the extent that any disruption or security
breach were to result in a loss of, or damage to, our or our third-party vendors’, collaborators’ or other contractors’
or consultants’ data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability
including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive
position could be harmed and the further development and commercialization of our product candidates could be delayed. Any of the above
could have a material adverse effect on our business, financial condition, results of operations or prospects.
Our insurance policies are expensive and
protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.
We do not carry insurance for all categories of
risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability,
property, inventory and cargo, auto, workers’ compensation, products liability, and directors’ and officers’ insurance.
We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant, uninsured
liability may require us to pay substantial amounts, which would adversely affect our working capital and results of operations.
If securities analysts do not publish research
or publish unfavorable research about our business, our stock price and trading volume could decline.
The trading market for a
company’s common stock often is based in part on the research and reports that securities and industry analysts publish about the
company. If additional analyst coverage does develop, and an analyst downgrades our stock or publishes unfavorable research about our
business, or if our clinical trials or operating results fail to meet the analysts’ expectations, our stock price would likely decline.
Changes in laws or regulations relating to data privacy and security,
or any actual or perceived failure by us to comply with such laws and regulations, or contractual or other obligations relating to data
privacy and security, could have a material adverse effect on our reputation, results of operations, financial condition and cash flows.
We are, and may increasingly become, subject to
various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which
we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing
requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws
and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they
will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations
or prospects.
In the U.S., various federal and state regulators,
including governmental agencies like the Consumer Financial Protection Bureau and the Federal Trade Commission, have adopted, or are considering
adopting, laws and regulations concerning personal information and data security. In particular, regulations promulgated pursuant to the
Health Insurance Portability and accountability Act of 1996 (“HIPAA”) establish privacy and security standards that limit
the use and disclosure of protected health information and require the implementation of safeguards to protect the privacy, integrity
and availability of protected health information. Determining whether protected health information has been handled in compliance with
applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. If we fail
to comply with applicable HIPAA privacy and security standards, we could face civil and criminal penalties. In addition, state attorneys
general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy
of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations.
Certain state laws may be more stringent or broader
in scope, or offer greater individual rights, with respect to personal information than federal, international, or other state laws, and
such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act
(“CCPA”), which increases privacy rights for California residents and imposes obligations on companies that process their
personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures
to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain
sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain
data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks
associated with, data breach litigation.
Internationally, laws, regulations and standards
in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal
information. For example, the E.U. General Data Protection Regulation (“GDPR”), which became effective in May 2018, greatly
increased the European Commission’s jurisdictional reach of its laws and adds a broad array of requirements for handling personal
data. EU member states are tasked under the GDPR to enact, and have enacted, certain implementing legislation that adds to and/or further
interprets the GDPR requirements and potentially extends our obligations and potential liability for failing to meet such obligations.
The GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing of personal
data, impose strict obligations and restrictions on the ability to collect, use, retain, protect, disclose, transfer and otherwise process
personal data. In particular, the GDPR includes obligations and restrictions concerning the consent and rights of individuals to whom
the personal data relates, the transfer of personal data out of the European Economic Area, security breach notifications and the security
and confidentiality of personal data. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or €20
million, whichever is greater.
All of these evolving compliance and operational
requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies,
training associates and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to
modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of
which could have a material adverse effect on our results of operations, financial condition and cash flows. Any failure or perceived
failure by us to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security
could result in damage to our reputation and our relationship with our customers, as well as proceedings or litigation by governmental
agencies or customers, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines,
sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results
of operations or prospects.
We review and explore strategic alternatives on an on-going basis,
but there can be no assurance that we will be successful in identifying or completing any strategic alternative or that any such strategic
alternative will yield additional value for our stockholders.
We regularly review strategic alternatives to
ensure our current structure optimizes our ability to execute our strategic plan and to maximize stockholder value. The review of strategic
alternatives could result in, among other things, a sale, merger, consolidation or business combination, asset divestiture, partnering,
licensing or other collaboration agreements, or potential acquisitions or recapitalizations, in one or more transactions, or continuing
to operate with our current business plan and strategy. There can be no assurance that the exploration of strategic alternatives will
result in the identification or consummation of any transaction.
In addition, we may incur substantial expenses
associated with identifying and evaluating potential strategic alternatives. The process of exploring strategic alternatives may be time
consuming and disruptive to our business operations and if we are unable to effectively manage the process, our business, financial condition
and results of operations could be adversely affected. We also cannot assure that any potential transaction or other strategic alternative,
if identified, evaluated and consummated, will provide greater value to our stockholders than that reflected in our current stock price.
Any potential transaction would be dependent upon a number of factors that may be beyond our control, including, among other factors,
market conditions, industry trends, the interest of third parties in our business or product candidates and the availability of financing
to potential buyers on reasonable terms.